MCID: AST005
MIFTS: 80

Asthma malady

Categories: Genetic diseases (common), Respiratory diseases

Aliases & Classifications for Asthma

About this section

Aliases & Descriptions for Asthma:

Name: Asthma 50 33 11 46 13 68 48 36 2 37 66
Chronic Obstructive Asthma 11 48 66
Bronchial Hyperreactivity 11 48 66
Asthma, Diminished Response to Antileukotriene Treatment in 50 12
Chronic Obstructive Asthma with Acute Exacerbation 11
Chronic Obstructive Asthma with Status Asthmaticus 11
Asthma, Protection Against 50
 
Asthma, Susceptibility to 25
Asthma, Exercise-Induced 66
Exercise Induced Asthma 11
Exercise-Induced Asthma 11
Asthma Exercise-Induced 48
Asthma, Nocturnal 50
Bronchial Asthma 68

Classifications:



Summaries for Asthma

About this section
MedlinePlus:36 Asthma is a chronic disease that affects your airways. your airways are tubes that carry air in and out of your lungs. if you have asthma, the inside walls of your airways become sore and swollen. that makes them very sensitive, and they may react strongly to things that you are allergic to or find irritating. when your airways react, they get narrower and your lungs get less air. symptoms of asthma include wheezing coughing, especially early in the morning or at night chest tightness shortness of breath not all people who have asthma have these symptoms. having these symptoms doesn't always mean that you have asthma. your doctor will diagnose asthma based on lung function tests, your medical history, and a physical exam. you may also have allergy tests. when your asthma symptoms become worse than usual, it's called an asthma attack. severe asthma attacks may require emergency care, and they can be fatal. asthma is treated with two kinds of medicines: quick-relief medicines to stop asthma symptoms and long-term control medicines to prevent symptoms. nih: national heart, lung, and blood institute

MalaCards based summary: Asthma, also known as chronic obstructive asthma, is related to atopy and churg-strauss syndrome, and has symptoms including recurring periods of wheezing (a whistling sound while breathing), chest tightness and shortness of breath. An important gene associated with Asthma is ADRB2 (Adrenoceptor Beta 2), and among its related pathways are Allograft rejection and G-protein signaling_RhoB regulation pathway. The drugs albuterol and aminophylline have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and t cells, and related mouse phenotypes are immune system and respiratory system.

Disease Ontology:11 A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors. the disease has symptom recurring periods of wheezing (a whistling sound while breathing), has symptom chest tightness, has symptom shortness of breath, has symptom mucus production and has symptom coughing. the symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.

NIH Rare Diseases:46 Asthma is a breathing disorder that affects the airways. people with this condition experience recurrent swelling and narrowing of the airways of the lungs which is associated with wheezing, shortness of breath, chest tightness, and coughing. most affected people have episodes of symptoms ("asthma attacks") followed by symptom-free periods; however, some may experience persistent shortness of breath in between attacks. asthma is considered a complex or multifactorial condition that is likely due to a combination of multiple genetic, environmental, and lifestyle factors. many people with asthma have a personal or family history of allergies, such as hay fever or eczema. having a family member with asthma is associated with an increased risk of developing the condition. treatment generally includes various medications, both to prevent asthma attacks and to provide quick relief during an attack. last updated: 2/28/2016

OMIM:50 Bronchial asthma is the most common chronic disease affecting children and young adults. It is a complex genetic... (600807) more...

Novus Biologicals:49 Asthma is a chronic lung disease that causes inflammation, thickening and narrowing of airways, as well as an overproduction of mucus. More than 300 million people worldwide suffer from asthma. Asthma symptoms include wheezing, shortness of breath, coughing and tightness of the chest. Interleukin 13 (IL-13) is the key effector cytokine in asthma. IL-13 stimulates airway fibrosis via action of matrix metalloproteinases (MMPs) on tumor transforming growth factor beta (TGN-beta), and also promotes epithelial damage, mucus production and an increased concentration of eosinophils. The inflammatory response characteristic of asthma is augmented by the production of IL-13 and other TH2 cytokines.

UniProtKB/Swiss-Prot:68 Asthma: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi.

Wikipedia:69 Asthma is a common long term inflammatory disease of the airways of the lungs. It is characterized by... more...

Related Diseases for Asthma

About this section

Diseases in the Asthma family:

Asthma 2 Asthma 1
Asthma, Phf11-Related

Diseases related to Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 446)
idRelated DiseaseScoreTop Affiliating Genes
1atopy33.8ADRB2, CCL11, HAVCR1, IL13, IL4R, IL5
2churg-strauss syndrome32.9IL13, IL5, RNASE3, TNF
3peanut allergy32.3IL5, RNASE3, TNF
4geotrichosis31.4CCL11, CYSLTR1, IL13, IL5, RNASE3, TNF
5keratoconjunctivitis31.2IL5, RNASE3
6allergic asthma12.4
7intrinsic asthma12.3
8asthma, aspirin-induced12.2
9asthma 212.1
10asthma 112.1
11cough variant asthma12.1
12asthma-related traits 712.0
13asthma susceptibility 512.0
14asthma-related traits 412.0
15asthma-related traits 312.0
16asthma-related traits 612.0
17asthma, phf11-related11.9
18asthma-related traits 811.8
19asthma susceptibility, adrb2-related11.8
20asthma susceptibility, ccl11-related11.8
21asthma susceptibility, hla-g-related11.8
22asthma susceptibility, il13-related11.8
23asthma susceptibility, muc7-related11.8
24asthma susceptibility, pla2g7-related11.8
25asthma susceptibility, scgb3a2-related11.8
26asthma susceptibility, tnf-related11.8
27asthma susceptibility, hnmt related11.8
28blind hypotensive eye11.5ADAM33, ADRB2, ALOX5, CCL11, CYSLTR1, IL13
29laryngeal tuberculosis11.5ADAM33, ADRB2, CCL11, CYSLTR1, IL13, IL5
30status asthmaticus11.5
31hepatic angiomyolipoma11.5CCL11, HAVCR1, IL13, IL5, NPSR1, PHF11
32biliary tract disease11.5CCL11, CYSLTR1, IL13, IL5, RNASE3, TNF
33dyskeratosis congenita11.4CCL11, IL13, IL5, NPSR1, PHF11, TNF
34autoimmune neuropathy11.4ADRB2, IL13, IL4R, IL5, RNASE3
35skin disease11.4IL13, IL4R, IL5, RNASE3, TNF
36dacryoadenitis11.4CCL11, CYSLTR1, IL13, IL5, RNASE3
37gait apraxia11.4CCL11, IL13, IL5, RNASE3, TNF
38vaginitis11.4CCL11, CYSLTR1, IL13, IL5, RNASE3
39sarcoid meningitis11.4CCL11, IL13, IL5, RNASE3, TNF
40loeffler syndrome11.4CCL11, IL13, IL5, RNASE3, TNF
41exophthalmos11.4CCL11, IL13, IL5, RNASE3, TNF
42hypertensive encephalopathy11.4CCL11, IL13, IL4R, IL5, RNASE3
43motion sickness11.4CCL11, IL13, IL5, RNASE3, TNF
44central nervous system origin vertigo11.4CCL11, IL13, IL5, RNASE3
45buphthalmos11.4CCL11, IL13, IL5, RNASE3
46bardet-biedl syndrome 811.4ADAM33, ADRB2, RNASE3, TNF
47melanoacanthoma11.4CCL11, IL13, IL5, RNASE3
48dentin caries11.4CCL11, IL13, IL5, RNASE3
49conventional malignant hemangiopericytoma11.4CCL11, IL13, IL5, RNASE3
50synostosis11.4CCL11, IL13, IL5, TNF

Comorbidity relations with Asthma via Phenotypic Disease Network (PDN):


Acute CystitisOsteoporosis
Respiratory FailureStatus Asthmaticus
BronchitisFamilial Atrial Fibrillation
Heart DiseaseHypertension, Essential

Graphical network of the top 20 diseases related to Asthma:



Diseases related to asthma

Symptoms for Asthma

About this section

Symptoms by clinical synopsis from OMIM:

600807

Clinical features from OMIM:

600807

Symptoms:

 11
  • recurring periods of wheezing (a whistling sound while breathing)
  • chest tightness
  • shortness of breath
  • mucus production
  • coughing

HPO human phenotypes related to Asthma:

id Description Frequency HPO Source Accession
1 asthma HP:0002099

UMLS symptoms related to Asthma:


coughing, dyspnea, hemoptysis, snoring, spasm, wheezing, injection site hypersensitivity, expiratory wheezing, asthmatic breathing, labored breathing

Drugs & Therapeutics for Asthma

About this section

FDA approved drugs:

(show all 16)
id Drug Name Active Ingredient(s)16 Company Approval Date
1
Accolate16 ZAFIRLUKAST AstraZeneca September 1999| October 1996
FDA Label: Accolate
Disease/s that Drug Treats:Asthma in pediatric patients
Indications and Usage:16 ACCOLATE is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.
DrugBank Targets:14 Cysteinyl leukotriene receptor 1
Mechanism of Action:16 
Target: leukotriene D4 and E4
Action: selective and competitive receptor antagonist
FDA: Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Patients with asthma were found in one study to be 25- 100 times more sensitive to the bronchoconstricting activity of inhaled LTD4 than nonasthmatic subjects. In vitro studies demonstrated that zafirlukast antagonized the contractile activity of three leukotrienes (LTC4, LTD4 and LTE4) in conducting airway smooth muscle from laboratory animals and humans. Zafirlukast prevented intradermal LTD4-induced increases in cutaneous vascular permeability and inhibited inhaled LTD4-induced influx of eosinophils into animal lungs. Inhalational challenge studies in sensitized sheep showed that zafirlukast suppressed the airway responses to antigen; this included both the early- and late-phase response and the nonspecific hyperresponsiveness. In humans, zafirlukast inhibited bronchoconstriction caused by several kinds of inhalational challenges. Pretreatment with single oral doses of zafirlukast inhibited the bronchoconstriction caused by sulfur dioxide and cold air in patients with asthma. Pretreatment with single doses of zafirlukast attenuated the early- and late-phase reaction caused by inhalation of various antigens such as grass, cat dander, ragweed, and mixed antigens in patients with asthma. Zafirlukast also attenuated the increase in bronchial hyperresponsiveness to inhaled histamine that followed inhaled allergen challenge.
2
Advair16 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
FDA Label: Advair
Disease/s that Drug Treats:asthma and chronic obstructive pulmonary disease
Indications and Usage:16 ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: * Treatment of asthma in patients aged 4 years and older. (1.1) * Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: * Not indicated for the relief of acute bronchospasm. (1.1, 1.2)
DrugBank Targets:14 14 Beta-2 adrenergic receptor|Glucocorticoid receptor|Progesterone receptor|Cytosolic phospholipase A2|Mineralocorticoid receptor
Mechanism of Action:16 
Target: -
Action: -
FDA: ADVAIR DISKUS: ADVAIR DISKUS contains both fluticasone propionate and salmeterol. The mechanisms of action described below for the individual components apply to ADVAIR DISKUS. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices. Fluticasone Propionate: Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma. Inflammation is also a component in the pathogenesis of COPD. In contrast to asthma, however, the predominant inflammatory cells in COPD include neutrophils, CD8+ T-lymphocytes, and macrophages. The effects of corticosteroids in the treatment of COPD are not well defined and inhaled corticosteroids and fluticasone propionate when used apart from ADVAIR DISKUS are not indicated for the treatment of COPD. Salmeterol Xinafoate: Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol. Although beta2- adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung. Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits plateletactivating factor-induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route. In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness.
3
Alvesco16 CICLESONIDE Nycomed January 2008
FDA Label: Alvesco
Disease/s that Drug Treats:asthma
Indications and Usage:16 ALVESCO is an inhaled corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. (1) ALVESCO is NOT indicated for the relief of acute bronchospasm. (1)
DrugBank Targets:14 Glucocorticoid receptor
Mechanism of Action:16 
Target: glucocorticoid receptors
Action: anti-inflammatory activity
FDA: Ciclesonide, is a prodrug, that is enzymatically hydrolyzed to a pharmacologically active metabolite, C21-desisobutyryl-ciclesonide (des-ciclesonide or RM1) following oral inhalation. Des-ciclesonide has anti-inflammatory activity with affinity for glucocorticoid receptors that is 120 times greater than the parent compound and 12 times greater than dexamethasone. The clinical significance of these findings is unknown. The precise mechanisms of corticosteroid action in asthma are unknown. Inflammation is recognized as an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in the asthmatic response. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma. Though effective for the treatment of asthma, corticosteroids do not affect asthma symptoms immediately. Individual patients will experience a variable time to onset and degree of symptom relief. Maximum benefit may not be achieved for four weeks or longer after starting treatment. When corticosteroids are discontinued, asthma stability may persist for several days or longer.
4
Arnuity Ellipta16 FLUTICASONE FUROATE GlaxoSmithKline August 2014
FDA Label: Arnuity Ellipta
Disease/s that Drug Treats:asthma
Indications and Usage:16 -
DrugBank Targets:14 Glucocorticoid receptor
Mechanism of Action:16 
Target: -
Action: anti-inflamatory
FDA: -
5
Azmacort16 TRIAMCINOLONE ACETONIDE Rhone Poulenc Rorer November 1996
FDA Label: Azmacort
Disease/s that Drug Treats:asthma
Indications and Usage:16 Azmacort Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy. Azmacort Inhalation Aerosol is also indicated for asthma patients who require systemic corticosteroid administration, where adding Azmacort may reduce or eliminate the need for the systemic corticosteroids. Azmacort Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm.
DrugBank Targets:14 Glucocorticoid receptor
Mechanism of Action:16 
Target: -
Action: -
FDA: The precise mechanism of the action of glucocorticoids in asthma is unknown. However, the inhaled route makes it possible to provide effective local anti-inflammatory activity with reduced systemic corticosteroid effects. Though highly effective for asthma, glucocorticoids do not affect asthma symptoms immediately. While improvement in asthma may occur as soon as one week after initiation of Azmacort Azmacort Azmacort Inhalation Aerosol therapy, maximum improvement may not be achieved for 2 weeks or longer.
6
Dulera16 FORMOTEROL FUMARATE; MOMETASONE FUROATE Merck June 2010
FDA Label: Dulera
Disease/s that Drug Treats:asthma
Indications and Usage:16 DULERA combines an inhaled corticosteroid medicine, mometasone furoate (the same medicine found in ASMANEX TWISTHALER), and a long-acting beta2-agonist medicine (LABA), formoterol (the same medicine found in FORADIL® AEROLIZER®). * Inhaled corticosteroids help to decrease inflammation in the lungs. Inflammation in the lungs can lead to asthma symptoms. * LABA medicines are used in people with asthma. LABA medicines help the muscles around the airways in your lungs stay relaxed to prevent asthma symptoms, such as wheezing and shortness of breath. These symptoms can happen when the muscles around the airways tighten. This makes it hard to breathe. In severe cases, wheezing can stop your breathing and may lead to death if not treated right away. DULERA is used to control symptoms of asthma and prevent symptoms such as wheezing in people 12 years of age and older. DULERA should not be used as a rescue inhaler. Do not use DULERA unless your healthcare provider has taught you and you understand everything. Ask your healthcare provider or pharmacist if you have any questions. * Use DULERA exactly as prescribed. Do not use DULERA more often than prescribed. DULERA comes in 2 strengths. Your healthcare provider has prescribed the strength that is best for you. Note the differences between DULERA and your other inhaled medications, including the differences in prescribed use and physical appearance. * DULERA should be taken every day as 2 puffs in the morning and 2 puffs in the evening. * If you miss a dose of DULERA, skip your missed dose and take your next dose at your regular time. Do not take DULERA more often or use more puffs than you have been prescribed. * While you are using DULERA 2 times each day, do not use other medicines that contain a longacting beta2-agonist (LABA) for any reason. Ask your healthcare provider or pharmacist if any of your other medicines are LABA medicines. * If you take more DULERA than your healthcare provider has prescribed, get medical help right away if you have any unusual symptoms, such as problems breathing, palpitations, chest pain, increased heart rate, nervousness or shakiness. * Do not change or stop using DULERA or other asthma medicines used to control or treat your breathing problems unless told to do so by your healthcare provider. Your healthcare provider will change your medicines as needed. * DULERA does not relieve sudden asthma symptoms. Always have a rescue inhaler with you to treat sudden symptoms. Use your rescue inhaler if you have breathing problems between doses of DULERA. If you do not have a rescue inhaler, call your healthcare provider to have one prescribed for you. * Remove the cap from the mouthpiece of the actuator before using DULERA. * DO NOT remove the canister from the actuator because: o You may not receive the correct amount of medication. o The dose counter may not function properly. o Reinsertion may cause the dose counter to count down by 1 and may discharge a puff. * Rinse your mouth with water after each dose (2 puffs) of DULERA. This will help to lessen the chance of getting a yeast infection (thrush) in the mouth and throat. * Do not spray DULERA in your eyes. If you accidentally get DULERA in your eyes, rinse your eyes with water and if redness or irritation continues, call your healthcare provider. * Call your healthcare provider or get medical care right away if: o your breathing problems worsen with DULERA o you need to use your rescue inhaler more often than usual o your rescue inhaler does not work as well for you at relieving symptoms o you need to use 4 or more inhalations of your rescue inhaler for 2 or more days in a row o you use 1 whole canister of your rescue inhaler in 8 weeks’ time o your peak flow meter results decrease. Your healthcare provider will tell you the numbers that are right for you. o you have asthma and your symptoms do not improve after using DULERA regularly for 1 to 2 weeks
DrugBank Targets:14 14 Beta-2 adrenergic receptor|Glucocorticoid receptor
Mechanism of Action:16 
Target: -
Action: -
FDA: -
7
Flovent Rotadisk16 FLUTICASONE PROPIONATE GlaxoSmithKline November 1997
FDA Label: Flovent Rotadisk
Disease/s that Drug Treats:asthma
Indications and Usage:16 FLOVENT Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time. FLOVENT Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm.
DrugBank Targets:14 Glucocorticoid receptor|Progesterone receptor|Cytosolic phospholipase A2|Mineralocorticoid receptor
Mechanism of Action:16 
Target: -
Action: -
FDA: The precise mechanisms of glucocorticoid action in asthma are unknown. Inflammation is recognized as an important component in the pathogenesis of asthma. Glucocorticoids have been shown to inhibit multiple cell types (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and mediator production or secretion (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in the asthmatic response. These anti-inflammatory actions of glucocorticoids may contribute to their efficacy in asthma.
8
Foradil Aerolizer16 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
FDA Label: Foradil Aerolizer
Disease/s that Drug Treats:COPD, asthma and bronchospasm
Indications and Usage:16 FORADIL AEROLIZER is a LABA indicated for: * Treatment of asthma in patients ≥5 years as an add-on to a long-term asthma control medication such as an inhaled corticosteroid. (1.1) * Prevention of exercise-induced bronchospasm (EIB) in patients ≥5 years. (1.2) * Maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD). (1.3) Important limitations of use: * NOT indicated for the relief of acute bronchospasm. (1.1, 1.3)
DrugBank Targets:14 Beta-2 adrenergic receptor
Mechanism of Action:16 
Target: beta2-adrenergic receptor|intracellular adenyl cyclase
Action: selective agonist|stimulant
FDA: Formoterol fumarate is a long-acting beta2-adrenergic receptor agonist (beta2-agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist activity at beta2-receptors than at beta1-receptors. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2-receptors in the human heart comprising 10%-50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including formoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that formoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Formoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness. The relevance of these in vitro and animal findings to humans is unknown.
9
Metaprotereol Sulfate16 METAPROTERENOL SULFATE Morton Grove Pharmaceuticals March 1997
FDA Label: -
Disease/s that Drug Treats:bronchial asthma and reversible bronchospasm
Indications and Usage:16 -
DrugBank Targets:14 Beta-2 adrenergic receptor
Mechanism of Action:16 
Target: -
Action: -
FDA: -
10
Nucala16 MEPOLIZUMAB GlaxoSmithKline November 2015
FDA Label: Nucala
Disease/s that Drug Treats:severe asthma
Indications and Usage:16 NUCALA® is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. [See Clinical Studies (14).] Limitations of Use * NUCALA is not indicated for treatment of other eosinophilic conditions. * NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.
DrugBank Targets:14 Interleukin-5
Mechanism of Action:16 
Target: interleukin-5
Action: antagonist monoclonal antibody (IgG1 kappa)
FDA: Mepolizumab is an interleukin-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. Mepolizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma has not been definitively established.
11
Qvar16 BECLOMETHASONE DIPROPIONATE Ivax May 2002
FDA Label: Qvar
Disease/s that Drug Treats:Asthma
Indications and Usage:16 QVAR is a corticosteroid indicated for: * Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. (1.1) * Treatment of asthma in patients who require oral corticosteroid therapy. QVAR may reduce or eliminate the need for the systemic corticosteroids. (1.1) Important Limitations: * Not indicated for the relief of acute bronchospasm. (1.1)
DrugBank Targets:14 Glucocorticoid receptor
Mechanism of Action:16 
Target: inflammatory cells
Action: inhibitor/anti-inflammatory
FDA: Beclomethasone dipropionate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and release of inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines). These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma. Beclomethasone dipropionate is a prodrug that is rapidly activated by hydrolysis to the active monoester, 17 monopropionate (17-BMP). Beclomethasone 17 monopropionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 13 times that of dexamethasone, 6 times that of triamcinolone acetonide, 1.5 times that of budesonide and 25 times that of beclomethasone dipropionate. The clinical significance of these findings is unknown. Studies in patients with asthma have shown a favorable ratio between topical anti-inflammatory activity and systemic corticosteroid effects with recommended doses of QVAR.
12
Rayos16 PREDNISONE Horizon Pharma July of 2012
FDA Label: Rayos
Disease/s that Drug Treats:certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions
Indications and Usage:16 RAYOS is a corticosteroid indicated * as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation (1) * for the treatment of certain endocrine conditions (1) * for palliation of certain neoplastic conditions (1)
DrugBank Targets:14 Glucocorticoid receptor|Corticosteroid 11-beta-dehydrogenase isozyme 1
Mechanism of Action:16 
Target: many organ systems
Action: anti-inflammatory
FDA: Naturally occurring corticosteroids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, such as prednisone, are primarily used for their potent antiinflammatory effects in disorders of many organ systems. Corticosteroids, such as prednisone, cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli. Prednisone is a synthetic adrenocortical steroid drug with predominantly corticosteroid properties. Some of these properties reproduce the physiological actions of endogenous glucocorticosteroids, but others do not necessarily reflect any of the adrenal hormones’ normal functions; they are seen only after administration of large therapeutic doses of the drug. The pharmacological effects of prednisone which are due to its corticosteroid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion. Depressed production of eosinophils and lymphocytes occurs, but erythropoiesis and production of polymorphonuclear leukocytes are stimulated. Inflammatory processes (edema, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis) and the later stages of wound healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension.
13
Serevent16 SALMETEROL XINAFOATE GlaxoSmithKline September 1997
FDA Label: Serevent
Disease/s that Drug Treats:asthma
Indications and Usage:16 SEREVENT DISKUS is a LABA indicated for: * Treatment of asthma in patients aged 4 years and older. (1.1) * Prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older. (1.2) * Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). (1.3) Important limitation: * Not indicated for the relief of acute bronchospasm. (1.1, 1.3)
DrugBank Targets:14 Beta-2 adrenergic receptor
Mechanism of Action:16 
Target: -
Action: -
FDA: Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung. Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits platelet-activating factor-induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route. In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness.
14
Singulair16 MONTELUKAST SODIUM Merck February 1998
FDA Label: Singulair
Disease/s that Drug Treats:asthma
Indications and Usage:16 SINGULAIR is a leukotriene receptor antagonist indicated for: * Prophylaxis and chronic treatment of asthma in patients 12 months of age and older (1.1). * Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older (1.2). * Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 6 months of age and older (1.3).
DrugBank Targets:14 Cysteinyl leukotriene receptor 1|Arachidonate 5-lipoxygenase
Mechanism of Action:16 
Target: -
Action: -
FDA: The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both earlyand late-phase reactions and are associated with symptoms of allergic rhinitis. Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β-adrenergic receptor). Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity.
15
Xolair16 OMALIZUMAB Genentech June 2003
FDA Label: Xolair
Disease/s that Drug Treats:asthma
Indications and Usage:16 Xolair is an anti-IgE antibody indicated for: * Moderate to severe persistent asthma in patients (12 years of age and above) with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids (1.1) * Chronic idiopathic urticaria in adults and adolescents (12 years of age and above) who remain symptomatic despite H1 antihistamine treatment (1.2) Limitations of use: * Not indicated for other allergic conditions or other forms of urticaria. (1.1, 1.2,) * Not indicated for acute bronchospasm or status asthmaticus. (1.1, 5.3)
DrugBank Targets:14 High affinity immunoglobulin epsilon receptor subunit alpha|High affinity immunoglobulin epsilon receptor subunit beta
Mechanism of Action:16 
Target: the binding of IgE to the high-affinity IgE receptor (Fc&RI)
Action: inhibitor
FDA: Asthma Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FcεRI-bearing cells limits the degree of release of mediators of the allergic response. Treatment with Xolair also reduces the number of FcεRI receptors on basophils in atopic patients. Chronic Idiopathic Urticaria Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (FcεRI) on cells down-regulate. The mechanism by which these effects of omalizumab result in an improvement of CIU symptoms is unknown.
16
Zyflo16 ZILEUTON Abbott Laboratories January 1997
FDA Label: Zyflo
Disease/s that Drug Treats:asthma
Indications and Usage:16 ZYFLO is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
DrugBank Targets:14 Arachidonate 5-lipoxygenase
Mechanism of Action:16 
Target: 5-lipoxygenase (5-LO)
Action: inhibitor
FDA: Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTC4, LTD4, and LTE4) formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Sulfido-peptide leukotrienes (LTC4, LTD4, LTE4, also known as the slow-releasing substances of anaphylaxis) and LTB4, a chemoattractant for neutrophils and eosinophils, can be measured in a number of biological fluids including bronchoalveolar lavage fluid (BALF) from asthmatic patients. Zileuton is an orally active inhibitor of ex vivo LTB4 formation in several species, including dogs, monkeys, rats, sheep, and rabbits. Zileuton inhibits arachidonic acidinduced ear edema in mice, neutrophil migration in mice in response to polyacrylamide gel, and eosinophil migration into the lungs of antigen-challenged sheep. Zileuton inhibits leukotriene-dependent smooth muscle contractions in vitro in guinea pig and human airways. The compound inhibits leukotriene-dependent bronchospasm in antigen and arachidonic acid-challenged guinea pigs. In antigen-challenged sheep, zileuton inhibits late-phase bronchoconstriction and airway hyperreactivity. In humans, pretreatment with zileuton attenuated bronchoconstriction caused by cold air challenge in patients with asthma.

Drugs for Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 519)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
OxycodonePhase 4, Phase 234776-42-65284603
Synonyms:
(-)-14-Hydroxydihydrocodeinone
(-)-Oxycodone
(5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one
124-90-3 (hydrochloride)
14-Hydroxydihydrocodeinone
14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one
25333-72-6 (Terephthalate)
4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5.alpha.-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
76-42-6
AC-16043
AC1Q4DTG
BRN 0043446
C08018
CHEBI:7852
CHEMBL656
CID5284603
Combunox
D05312
DB00497
DEA No. 9143
Dihydro-14-hydroxycodeinone
Dihydrohydroxycodeinone
Dihydrohydroxycondeinone
Dihydrone
Dihydroxycodeinone
Dinarkon
Diphydrone
EINECS 200-960-2
Endine (Australia)
Endocet
Endodan
Endone
Eubine
Eubine [France]
Eucodal
Eucodalum
Eukodal
Eutagen
HSDB 3142
Hydroxycodeinon
LS-92148
MolPort-004-285-989
Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl- (8CI)
NSC 19043
NSC19043
 
Ossicodone
Ossicodone [DCIT]
Oxanest
Oxicodona
Oxicodona [INN-Spanish]
Oxicon
Oxicone
Oxiconum
Oxikon
OxyFAST
OxyIR
OxyNorm
Oxycodeinon
Oxycodeinone
Oxycodon
Oxycodone
Oxycodone (USAN/INN)
Oxycodone Concentrate
Oxycodone Hcl
Oxycodone Hydrochloride
Oxycodone [USAN:INN:BAN]
Oxycodone hydrochloride
Oxycodonum
Oxycodonum [INN-Latin]
Oxycon
Oxycone
Oxycontin
Oxyfast
Oxynorm
PTI-821
Pancodine
Pancodone retard (United Kingdom)
Percobarb
Percodan
Percolone
Remoxy
Roxicet
Roxicodone
Supendol
Supendol [Canada]
Supeudol
Tecodin
Tekodin
Tekodin (free base)
Thecodine
Thekodin
Theocodin
UNII-CD35PMG570
WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JO1 P1
oxycodone
2
KetorolacPhase 4, Phase 3, Phase 2, Phase 129174103-06-3, 66635-83-43826
Synonyms:
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-Ketorolac
(+-)-isomer
(.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid
1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro
5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
66635-83-4
74103-06-3
AB00053682
AC-545
AC1L1GSW
BRD-A40639672-234-05-7
C07062
CHEBI:105080
CHEMBL469
CID3826
D020910
D08104
DB00465
 
I14-2832
Ketoralac
Ketorolac
Ketorolac (INN)
Ketorolac Tromethamine
Ketorolac [INN:BAN]
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
Kétorolac
LS-139094
Macril
MolPort-005-933-093
NCGC00185990-01
RS 37619
RS-37619
SBB067312
STL018674
Toradol (TN)
UNII-YZI5105V0L
ketorolac
rac-Ketorolac
3
LatanoprostPhase 4196130209-82-45282380, 5311221
Synonyms:
130209-82-4
AC1NSK8Q
AR-202
Ambap130209-82-4
CHEBI:6384
CHEMBL1051
CID5311221
CPD000466354
Catioprost
D00356
HMS2051H11
HMS2089J17
Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Jsp001835
L1167_SIGMA
Latanoprost
Latanoprost (JAN/USAN/INN)
Latanoprostum
MLS000759468
MLS001424106
 
MolPort-003-942-862
Nova-21027
PHXA-41
PhXA 41
PhXA34 [as 15(R,S)-isomer]
PhXA41
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
S1254_Selleck
SAM001246671
SMR000466354
TL8000716
XA-41
XA41
Xalatan
Xalatan (TN)
Xalatan Fixed Flow Device
ZINC12468792
isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
latanoprost
latanoprost free acid
propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
4
EsmololPhase 452103598-03-4, 81147-92-459768
Synonyms:
(+-)-Esmolol
(+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
(±)-esmolol
(±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
103598-03-4
3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester
81147-92-4
81161-17-3 (Hydrochloride)
84057-94-3
AC-12058
AC1L1RWQ
AC1Q5ZXA
ASL 8052-001
BRN 5287174
Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester
C06980
CHEBI:4856
 
CHEMBL768
CID59768
D07916
DB00187
ESMOLOL
Esmolol (INN)
Esmolol [INN:BAN]
HMS2090P06
L001332
LS-185019
LS-31121
Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate
MolPort-005-933-593
UNII-MDY902UXSR
methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate
methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate
methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate
methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate
5
OndansetronPhase 4, Phase 329699614-02-54595
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
99614-01-4 (mono-hydrochloride)
99614-02-5
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
GR 38032
GR 38032X
GR-38032F
GR38032F
HMS2090H16
I06-0687
I06-1329
 
L000456
LS-172305
LS-51878
MolPort-001-944-253
NCI60_022780
Novo-ondansetron
Ondansetron
Ondansetron (JAN/USP/INN)
Ondansetron [USAN:INN:BAN]
Ondansetron, (+,-)-Isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
SN-307
SPBio_002938
STK370548
STOCK4S-10990
Sandoz ondansetron
TL8006071
TimTec1_001750
UNII-4AF302ESOS
ZOFRAN IN PLASTIC CONTAINER
Zofran
Zofran ODT
Zofran ODT (TN)
Zofran odt
Zophren
Zudan
ondansetron
ondansetron (Zofran)
6
MorphinePhase 4, Phase 3, Phase 2, Phase 191357-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
Infumorph
Kadian
 
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morphine
nchembio.317-comp1
nchembio.64-comp1
7
FentanylPhase 4, Phase 2, Phase 3, Phase 1739437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
8
ChlorhexidinePhase 444855-56-19552079, 2713
Synonyms:
1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]
1,1'-Hexamethylene bis(5-(P-chlorophenyl)biguanide)
1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide
1,6-Bis(5-(p-chlorophenyl)biguandino)hexane
1,6-Bis(p-chlorophenyldiguanido)hexane
1,6-Di(4'-chlorophenyldiguanido)hexane
1,6-Di(N-p-chlorophenyldiguanido)hexane
24798_FLUKA
282227_ALDRICH
348031_ALDRICH
4-12-00-01201 (Beilstein Handbook Reference)
55-56-1
AB00053427
AB1003159
AVAGARD
BPBio1_000272
BRN 2826432
BSPBio_000246
BSPBio_001977
C06902
C22H30Cl2N10
CAS-55-56-1
CCRIS 9230
CHEBI:3614
CHEMBL790
CID9552079
Chlorhexidin
Chlorhexidin [Czech]
Chlorhexidine
Chlorhexidine (INN)
Chlorhexidine Base
Chlorhexidine [INN:BAN]
Chlorhexidine gluconate
Chlorhexidinum
Chlorhexidinum [INN-Latin]
Cloresidina
Cloresidina [DCIT]
Clorhexidina
Clorhexidina [INN-Spanish]
D07668
DB00878
Decanoylacetaldehyde Sodium Sulfide
Dentisept [veterinary]
Dentisept [veterinary] (TN)
DivK1c_000761
EINECS 200-238-7
Fimeil
HMS1568M08
HSDB 7196
Hexadol
Hibiclens
Hibispray
Hibistat
I06-0621
I14-0050
IDI1_000761
 
KBio1_000761
KBio2_000717
KBio2_003285
KBio2_005853
KBio3_001197
KBioGR_000774
KBioSS_000717
LS-43917
Lisium (*Dihydrochloride*)
MK-412A
MLS001332387
MLS001332388
MLS002154209
Merfen-incolore
Merfen-incolore (TN)
MolPort-002-541-741
N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
NCGC00016246-01
NCGC00091025-01
NCGC00091025-02
NINDS_000761
NSC526936
Nolvasan
Nolvasan (*Diacetate*)
Novalsan
Oro-Clense
Peridex
Periogard
Prestwick0_000143
Prestwick1_000143
Prestwick2_000143
Prestwick3_000143
Prestwick_53
QTL1_000020
Rotersept
SMR000857146
SPBio_000210
SPBio_002185
STK089248
STOCK1S-18831
Savloclens
Savlon babycare
Sebidin A
Sodium Houttuyfonamide
Soretol
Spectrum2_000135
Spectrum3_000339
Spectrum4_000277
Spectrum5_001322
Spectrum_000237
Sterido
Sterilon
Superspray
Tubulicid
UNII-R4KO0DY52L
chlorhexidine
9Chlorhexidine gluconatePhase 4448
10
MepivacainePhase 45696-88-84062
Synonyms:
(+-)-1-Methyl-2',6'-pipecoloxylidide
1-METHYL-2',6'-PIPECOLOXYLIDIDE
1-methyl-2',6'-pipecoloxylidide
1722-62-9 (mono-hydrochloride)
22801-44-1
34811-66-0
5-22-01-00223 (Beilstein Handbook Reference)
96-88-8
AC-15503
AC1L1HBV
Arestocaine HCL
BRD-A03216249-003-02-9
BRN 0211230
BSPBio_003297
C07528
CHEBI:6759
CHEMBL1087
CID4062
Carbocaine
Carboplyin Dental
Carboplyin Dental (TN)
D(-)-Mepivacaine
D-mepivacaine
D08181
DB00961
DL-Mepivacaine
DivK1c_006970
EINECS 202-543-0
I01-1864
Isocaine HCL
KBio1_001914
KBio2_001960
KBio2_004528
KBio2_007096
 
KBio3_002517
KBioGR_001092
KBioSS_001960
LS-109848
LS-109849
Mepivacaina
Mepivacaina [INN-Spanish]
Mepivacaine (INN)
Mepivacaine HCL
Mepivacaine [INN:BAN]
Mepivacaine hydrochloride
Mepivacainum
Mepivacainum [INN-Latin]
Mepivicaine
MolPort-005-935-383
N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide
N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide
N-Methyl-2-pipecolic acid, 2,6-dimethylanilide
N-Methyl-2-pipecolic acid, 2,6-xylidide
N-Methylhexahydro-2-picolinic acid, 2,6-dimethylanilide
NCGC00089774-02
Polocaine-Mpf
S-Ropivacaine Mesylate
SPBio_001811
Scandicain
Scandicaine
Scandicane
SpecPlus_000874
Spectrum2_001656
Spectrum3_001629
Spectrum4_000596
Spectrum5_001354
Spectrum_001480
UNII-B6E06QE59J
mepivacaine
11
NeostigminePhase 4, Phase 2, Phase 39459-99-44456
Synonyms:
(m-Hydroxyphenyl)trimethylammonium dimethylcarbamate
(m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester)
114-80-7 (bromide)
3-Trimethylammoniumphenyl N,N-dimethylcarbamate
3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium
3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium
51-60-5 (methyl sulfate)
59-99-4
AB00053807
AC1L1I7G
Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester)
BPBio1_000634
BRD-K18922609-004-04-1
BRN 3615946
BSPBio_000576
Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl- (9CI)
C07258
CAS-114-80-7
CCRIS 3079
CHEBI:7514
CID4456
D08261
DB01400
DivK1c_000165
DivK1c_000198
Eustigmin
Eustigmine
HMS2089A22
HSDB 3921
IDI1_000165
IDI1_000198
InChI=1/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
Intrastigmina
Juvastigmin
KBio1_000165
KBio1_000198
KBio2_001541
KBio2_004109
KBio2_006677
KBioGR_000623
KBioSS_001541
LS-18452
Lopac-N-2001
 
Lopac0_000816
NCGC00015730-01
NCGC00015730-02
NCGC00015730-03
NCGC00015730-04
NCGC00015730-08
NCGC00021658-03
NCGC00163240-01
NEOSTIGMINE
NINDS_000165
NINDS_000198
Neostigmin
Neostigmine (BAN)
Neostigmine [BAN]
Neostigmine omega
Neostigminum
Prestwick0_000468
Prestwick1_000468
Prestwick2_000468
Prestwick3_000468
Prostigmin
Prostigmin (TN)
Prostigmine
Prozerin
SPBio_001276
SPBio_002515
STL058953
Spectrum2_001278
Spectrum4_000072
Spectrum5_001234
Spectrum_001061
Synstigmin
Syntostigmine
UNII-3982TWQ96G
Vagostigmin
Vagostigmine
ZINC00001792
[3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium
[3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide
[3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium
bmse000762
m-Trimethylammoniumphenyldimethylcarbamate
nchembio.188-comp33
sulfonatooxymethane
12Vecuronium BromidePhase 4, Phase 33050700-72-6
13EMLAPhase 464
14
HexetidinePhase 45141-94-6
Synonyms:
 
Esetidina
Hexétidine
15
DesfluranePhase 413257041-67-542113
Synonyms:
(+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
1,1,1,2-Tetrafluoro-2-(difluoromethoxy)ethane
1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane
2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
57041-67-5
AC1L274J
AC1Q4ICY
C07519
C3H2F6O
CHEBI:4445
CHEMBL1200733
CID42113
D00546
DB01189
DESFLURANE
Desflurane
 
Desflurane (JAN/USP/INN)
Desflurane [USAN:INN]
Desflurano
Desflurano [INN-Spanish]
Desfluranum
Desfluranum [INN-Latin]
Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
I 653
I-653
I653
LS-65505
MolPort-001-776-387
PC6781E
Suprane
Suprane (TN)
UNII-CRS35BZ94Q
difluoromethyl 1,2,2,2-tetrafluoroethyl ether
r-e 236ea1
16
MoxifloxacinPhase 4, Phase 1423354812-41-2, 151096-09-2152946
Synonyms:
(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
151096-09-2
186826-86-8
192927-63-2
7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
AC1L49EP
Actira (*Hydrochloride*)
Avelox
Avelox (*Hydrochloride*)
Avelox I.V.
BAY 12-8039
 
BAY 12-8039 (*Hydrochloride*)
CCRIS 8690
CHEMBL32
CID152946
DB00218
I06-1961
LS-141510
MFX
MXF
MXFX
Moxifloxacin [INN:BAN]
UNII-U188XYD42P
Vigamox
moxifloxacin
17
clonidinePhase 4, Phase 32194205-90-72803
Synonyms:
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI)
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2,6-dichloro-N-(2-imidazolidinylidene)aniline
2,6-dichloro-N-2-imidazolidinylidenebenzenamide
2,6-dichloro-N-imidazolidin-2-ylideneaniline
2-((2,6-Dichlorophenyl)imino)imidazolidine
2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2)
2-(2,6-Dichloroanilino)-2-imidazoline
2-(2,6-Dichlorophenylamino)-2-imidazoline
2-(2,6-Dichlorophenylimino)imidazolidine
2-Imidazoline, 2-(2,6-dichloroanilino)- (7CI,8CI)
2-[(2,6-Dichlorophenyl)imino]imidazoline
2-[(2,6-dichlorophenyl)imino]-2-imidazoline
4205-90-7
4205-91-8 (mono-hydrochloride)
57066-25-8
734571A
AB00514634
AC1L1EI5
AC1Q3K6V
AKOS001595470
Adesipress
BIDD:GT0547
BPBio1_000040
BRD-K98530306-001-02-1
BRD-K98530306-003-05-0
BSPBio_000036
BSPBio_001588
BSPBio_002055
Bio1_000470
Bio1_000959
Bio1_001448
Bio2_000308
Bio2_000788
C9H9Cl2N3
CAS-4205-91-8
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
CCRIS 7787
CHEBI:3757
CHEBI:46632
CHEMBL134
CID2803
Catapres
Catapres- TTS
Catapres-TTS
Catapresan
Catapressan
Catarpres
Catarpres-TTS
Catarpres-TTS (TN)
Catarpresan
Chlofazoline
Chlornidinum
Clofenil
Clonidin
Clonidina
Clonidina [INN-Spanish]
Clonidine (JAN/USAN/INN)
Clonidine HCl
Clonidine [USAN:BAN:INN]
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
D00281
DB00575
DB07566
DivK1c_000774
 
Dixarit
Duraclon
Duraclont
EINECS 224-119-4
Gemiton
HMS1361P10
HMS1791P10
HMS1989P10
HMS2089G11
HSDB 3040
Hemiton
IDI1_000774
IDI1_034058
Ipotensium
Isoglaucon
KBio1_000774
KBio2_000308
KBio2_001821
KBio2_002876
KBio2_004389
KBio2_005444
KBio2_006957
KBio3_000615
KBio3_000616
KBio3_001275
KBioGR_000308
KBioGR_001572
KBioSS_000308
KBioSS_001821
Klofelin
Klofenil
L000193
LS-79606
Lopac-C-7897
Lopac0_000268
M 5041T
M-5041T
MolPort-001-779-668
MolPort-005-932-374
N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
NCGC00015268-01
NCGC00015268-02
NCGC00015268-08
NCGC00024734-01
NCGC00024734-02
NCGC00024734-03
NCGC00024734-04
NCGC00024734-05
NCGC00179680-01
NINDS_000774
Prestwick0_000248
Prestwick1_000248
Prestwick2_000248
Prestwick3_000248
SKF 34427
SPBio_001233
SPBio_002255
ST 155BS
ST-155-BS
ST-155BS
Spectrum2_001187
Spectrum3_000358
Spectrum4_000956
Spectrum5_000759
Spectrum_001341
T171
Tenso-Timelets
Tocris-0690
UNII-MN3L5RMN02
ZINC00896484
clonidine
nchembio.79-comp11
nchembio705-10
18
PhenylpropanolaminePhase 4, Phase 3, Phase 2, Phase 160314838-15-426934
Synonyms:
(+)-Norephedrine
(+-)-Norephedrin
(+-)-Norephedrine
(+/-)-Norephedrin
(-)-Norephedrin
(-)-Norephedrine
(.+-.)-Norephedrine
(1R,2S)-Norephedrine
.psi.-Norephedrine
134-60-1
14838-15-4
16960-27-3
1926-74-5
2-amino-1-phenylpropan-1-ol
27818-48-0
282553_ALDRICH
317500_ALDRICH
36393-56-3
36393-57-4
37577-07-4
37577-28-9
48115-38-4
492-39-7
492-41-1
6891-23-2
700-65-2
74530_FLUKA
AB00375975
AB1001936
AC1L1C6K
AC1L1IYB
AC1L1UWH
AC1L4QZI
AC1Q59PM
AR-1J0987
AR-1J0988
Acutrim
Ami-Tex
BIDD:GT0376
BPBio1_000361
BRN 2802895
BRN 3196918
BSPBio_000327
BSPBio_003292
C02343
C07911
C16719
C9H13NO
CHEBI:327494
CHEMBL136560
CID10297
CID162265
CID26934
CID4786
Cathina
Cathine
Cathine [INN]
Cathinum
Cathinum [INN-Latin]
Codimal
Conex
Contuss
D-(+)-Norephedrine
D08368
DB00397
DEA No. 1230
DL-Norephedrine
DL-Phenylpropanolamine
Despec
Dexatrim
DivK1c_000795
DivK1c_007030
Dura-Vent
EINECS 207-754-1
EINECS 207-755-7
EINECS 211-850-9
EINECS 238-900-2
EINECS 253-014-6
Exponcit
Fansia
Fansia (TN)
Fenilpropanolamina
Fugoa
Fugoa Depot
Gentab
Guaipax
HMS2090P12
HSDB 6485
Hydriatine
I01-8913
I01-8924
IDI1_000795
KBio1_000795
KBio1_001974
KBio2_001583
KBio2_004151
 
KBio2_006719
KBio3_001778
KBio3_002512
KBioGR_001385
KBioGR_001950
KBioSS_001583
Katine
L-(-)-Norephedrine
L-NOREPHEDRINE
L-Phenyl Propanolamine
L001077
LS-176795
LS-97284
LS-97285
LS-97461
LS-97462
Minusine
MolPort-001-769-340
MolPort-001-788-006
MolPort-001-794-194
MolPort-001-794-233
Mucorama
Mucron
Mydriatin
Myminic
NCGC00178157-01
NCGC00178157-02
NINDS_000795
NSC 17704
NSC 9920
NSC120735
NSC17704
NSC9920
Nobese
Nolex
Norephedrin
Norephedrine
Norpseudoephedrine
Obestat
PDSP1_001348
PDSP1_001349
PDSP1_001354
PDSP2_001332
PDSP2_001333
PDSP2_001338
PPA
Partuss
Phenoxine
Phenyldrine
Phenylfenesin
Phenylpropanolamin
Phenylpropanolamina
Phenylpropanolamine
Phenylpropanolaminum
Phénylpropanolamine
Prestwick0_000324
Prestwick1_000324
Prestwick2_000324
Prestwick3_000324
Prestwick_388
Propadrine
Propagest
Pseudonorephedrine
Rhindecon
Rhymed
SPBio_000051
SPBio_000471
SPBio_002248
SPECTRUM2300253
Snaplets
SpecPlus_000934
Spectrum2_000016
Spectrum2_000516
Spectrum3_000889
Spectrum3_001706
Spectrum4_000983
Spectrum4_001685
Spectrum5_000330
Spectrum5_001156
Spectrum_001103
Super Odrinex
TAVIST-D
ULR
UNII-33RU150WUN
UNII-E1L4ZW2F8O
USAF CS-6
Vanex
WLN: ZY1&YQR
WLN: ZY1&YQR -L
d-Nor-psi-ephedrine
d-Norpseudoephedrine
dl-Norephedrine
l-Nor-psi-ephedrin
l-Nor-psi-ephedrine
l-Norephedrine
phenylpropanolamine
psi-Norephedrine
β-hydroxyamphetamine
19
Maleic acidPhase 4, Phase 2, Phase 3, Phase 1292110-16-7444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
20
PrilocainePhase 477721-50-64906
Synonyms:
2-(Propylamino)-O-propionotoluidide
2-(Propylamino)-o-propionotoluidide
2-Methyl-.alpha.-propylaminopropionanilide
2-Methyl-alpha-propylaminopropionanilide
721-50-6
AB00053665
AC-2100
AC1L1J7W
Ambap1786-81-8
Astra 1512
Astra 1515
BPBio1_000173
BRD-A53952395-003-05-3
BRN 2108498
BSPBio_000157
BSPBio_002604
C07531
C13H20N2O
CHEBI:8404
CHEMBL1194
CID4906
Citanest
Citanest Plain
D00553
DB00750
DivK1c_000846
EINECS 211-957-0
HSDB 3386
I01-1860
IDI1_000846
KBio1_000846
KBio2_002129
KBio2_004697
KBio2_007265
KBio3_001824
KBioGR_001883
KBioSS_002129
L 67
LS-2304
Lopac0_001005
MolPort-005-935-583
 
N-(2-Methylphenyl)-2-(propylamino)propanamide
N-(2-methylphenyl)-N(2)-propylalaninamide
N-(2-methylphenyl)-N2-propylalaninamide
N-[2-Methylphenyl]-2-[propylamino]propanamide
NCGC00015860-03
NCGC00162312-01
NINDS_000846
NSC 40027
NSC40027
O-Methyl-2-propylaminopropionanilide
O-Methyl-alpha-propylaminopropionanilide
Prestwick0_000199
Prestwick1_000199
Prestwick2_000199
Prestwick3_000199
Prilocain
Prilocaina
Prilocaina [INN-Spanish]
Prilocaine (USP/INN)
Prilocaine [USAN]
Prilocaine base
Prilocainum
Prilocainum [INN-Latin]
Prilocaïne
Propanamide, N-(2-methylphenyl)-2-(propylamino)- (9CI)
Propitocaine
Propitocaine (JAN)
S1619_Selleck
SPBio_001398
SPBio_002078
Spectrum2_001549
Spectrum3_001052
Spectrum4_001192
Spectrum5_001175
Spectrum_001649
UNII-046O35D44R
alpha-N-Propylamino-2-methylpropionanilide
alpha-n-Propylamino-2-methylpropionanilide
o-Methyl-2-propylaminopropionanilide
o-Methyl-alpha-propylaminopropionanilide
prilocaine
prilocaine base
21
ChlorpheniraminePhase 4, Phase 3, Phase 2, Phase 169113-92-8, 132-22-92725
Synonyms:
1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine
1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
113-92-8
132-22-9
2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine
3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine
3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
4-Chloropheniramine
42882-96-2
46970-45-0
AC1L1EBQ
AKOS001650136
Aller-Chlor
Allergican
Allergisan
Antagonate
BPBio1_000148
BRD-A04553218-050-03-0
BSPBio_000134
C06905
C16H19ClN2
CHEBI:52010
CHEMBL505
CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8))
CID2725
Chlo-amine
Chlor-Pro
Chlor-Trimeton Repetabs
Chlor-trimeton
Chloropheniramine
Chloropheniramine maleate
Chlorophenylpyridamin
Chlorophenylpyridamine
Chloropiril
Chloroprophenpyridamine
Chlorphenamine
Chlorphenamine (INN)
Chlorphenamine Maleate
Chlorphenamine [INN]
Chlorphenamine hydrogen maleate
Chlorphenaminum
Chlorphenaminum [INN-Latin]
Chlorpheniaramine maleate
Chlorpheniramine
Chlorpheniramine Maleate
Chlorpheniraminum
Chlorprophenpyridamine
 
Clofeniramina
Clofeniramina (TN)
Clorfenamina
Clorfenamina [INN-Spanish]
Clorfeniramina
Clorfeniramina [Italian]
Cloropiril
D07398
DB01114
DivK1c_000596
EINECS 205-054-0
Gen-Allerate
HMS2090M21
HSDB 3032
Haynon
Hayon
Histadur
IDI1_000596
ISOCLOR
KBio1_000596
Kloromin
L000003
LS-754
Lopac0_000261
MolPort-002-507-837
NCGC00015227-05
NCGC00162108-01
NINDS_000596
Novo-Pheniram
Oprea1_779072
Pediacare Allergy Formula
Phenetron
PiriIton
Piriton
Polaronil
Prestwick0_000117
Prestwick1_000117
Prestwick2_000117
Prestwick3_000117
SPBio_002073
STK736174
STOCK5S-99837
Telachlor
Teldrin
UNII-3U6IO1965U
[3H]Chlorpheniramine
chlorpheniramine
gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine
gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine
22
DextromethorphanPhase 4, Phase 1127125-71-35360696, 5362449
Synonyms:
( )-3-Methoxy-N-methylmorphinon
( )-cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren
(+)-3-Methoxy-17-methylmorphinan
(+)-dextromethorphan
(-)-3-Methoxy-N-methylmorphinan
(9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan
125-69-9 (hydrobromide)
125-70-2
125-71-3
18046-32-7
18609-21-7 (hydrochloride)
3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan
3-Methoxy-17-methylmorphinan
32062-10-5
4-21-00-01367 (Beilstein Handbook Reference)
6700-34-1 (hydrobromide, mono-hydrate)
9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl- (8CI)
AC-13098
AC1L1EYT
Albutussin
Antussan
BA 2666
BPBio1_000503
BRD-K33211335-337-03-7
BRN 0088549
BSPBio_000457
Balminil DM
Balminil DM Children
Bayer Select Flu Relief
Bayer Select Head & Chest Cold
Bayer Select Night Time Cold
Benylin Adult Formula Cough Suppressant
Benylin DM
Benylin DM (TN)
Benylin DM 12 Hour
Benylin DM for Children
Benylin DM for Children 12 Hour
Benylin Pediatric Cough Suppressant
C06947
CHEBI:128891
CHEBI:4470
CHEBI:580686
CHEMBL22207
CHEMBL52440
CID3008
CID5360696
CID5362449
Calmylin #1
Canfodion
Cerose-DM
Chloraseptic DM
Contac Day & Night Cold/Flu Day Caplets
Contac Jr. Non-drowsy Formula
Contac Nighttime Cold Medicine
Contac Severe Cold Formula Maximum Strength
Contac Severe Cold Formula Non-Drowsy
Coricidin Syrup
Cosylan
Cough-X
Creo-Terpin
D-Methorphan
D-Methorphan Hydrobromide
D-methorphan
D03742
DB00514
DEA No. 9210
DM
DXM
Delsym
Delsym Cough Formula
Delta-Methorphan
Demorphan
Demorphan Hydrobromide
Demorphan hydrobromide
Demorphine
Destrometerfano
Destrometerfano [DCIT]
Destrometerfano [Dcit]
Dex
Dextromethorfan
Dextromethorfan [Czech]
Dextromethorphan
Dextromethorphan (USP)
Dextromethorphan Bromhydrate
Dextromethorphan Bromide
Dextromethorphan [USP:INN:BAN]
Dextromethorphan hydrobromide OROS Tablets
Dextromethorphan hydrobromide [BAN:JAN]
Dextromethorphan hydrobromide monohydrate
Dextromethorphane
Dextromethorphane [INN-French]
Dextromethorphanum
Dextromethorphanum [INN-Latin]
Dextrometorfano
Dextrometorfano [INN-Spanish]
Dextrometorphan
Dextromorphan
Dextrométhorphane
Dexyromethorphan
Diabe-Tuss DM Syrup
 
Dimacol
Dimetapp DM
Dormetan
Dormethan
Drixoral Cough
Drixoral Cough & Congestion
Drixoral Cough & Sore Throat
EINECS 204-751-7
EINECS 204-752-2
Endotussin-NN
Endotussin-NN Pediatric
HMS2090C08
HSDB 3056
Hihustan M.
Hold
Hold DM
Koffex DM
L-Methorphan
LS-91837
LS-91838
Levomethorphan
Levomethorphan [BAN:DCF:INN]
Levomethorphan [Ban:Dcf:Inn]
Levomethorphan [INN:BAN:DCF]
Levomethorphane
Levomethorphane [INN-French]
Levomethorphanum
Levomethorphanum [INN-Latin]
Levometorfano
Levometorfano [INN-Spanish]
Lopac-D-2531
Lopac0_000337
MLS000758303
Medicon
Methorate
Methorate Hydrobromide
Methorphan
Metrorat
MolPort-003-940-943
MolPort-004-285-957
Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)- (9CI)
NCGC00015333-01
NCGC00015333-02
NCGC00015333-04
NCGC00162126-01
Naldecon-DX
Novahistex DM
Novahistine DM
Ornex Severe Cold Formula
Orthoxicol
PediaCare 1
PediaCare Cough-Cold Formula
Pertussin CS Children's Strength
Pertussin DM Extra Strength
Prestwick0_000359
Prestwick1_000359
Prestwick2_000359
Prestwick3_000359
Prestwick_686
RACEMETHORPHAN
Robitussin CF
Robitussin Cold & Cough
Robitussin Cough Calmers
Robitussin DM
Robitussin Maximum Strength Cough
Robitussin Maximum Strength Cough Suppressant
Robitussin Pediatric
Robitussin Pediatric Cough
Robitussin Pediatric Cough & Cold
Robitussin Pediatric Cough Suppressant
Robitussin Pediatric Night Relief
Romilar
Rondec dm
Ru-Tuss Expectorant
SPBio_002378
St. Joseph Cough Syrup
Sucrets 4 Hour Cough Suppressant
Sudafed Cough Syrup
Triaminic
Triaminic DM Long Lasting for Children
Trind-DM
Trocal
Tusilan
Tussade
Tussar DM
Tussi-Organidin
Tussi-Organidin DM NR
Tussi-Organidin DM-S NR
Tylenol Cold No Drowsiness
Tylenol Cold and Flu Multi-Symptom
Tylenol Cold and Flu No Drowsiness
Tylenol Cough + Decongestant Liquid
Tylenol Cough Liquid
Tylenol Flu No Drowsiness Gelcaps
UNII-7355X3ROTS
Vicks 44 Cough Relief
Viro-Med
d-Methorphan
delta-Methorphan
dextromethorphan
l-Methorphan
23
GuaifenesinPhase 4, Phase 3, Phase 2, Phase 160393-14-13516
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
Amonidren
Amonidrin
Aresol
Benylin-E
Bronchol
Glycerin ether
Glycerin guaiacolate
Glycero-guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
 
Glycerylguaiacol
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
Guaifenesine
Guaiphenesin
Guaiphenesine
Guaiphesin
Hustosil
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
O-Methoxyphenyl glyceryl ether
Organidin NR
Pneumomist
Propanosedyl
Reduton
Robitussin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
guaiphenesin
p-Cresyl acetate
24
TacrolimusPhase 4, Phase 3, Phase 2, Phase 11058104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
25
PimecrolimusPhase 4, Phase 3, Phase 162137071-32-06447131, 17753757
Synonyms:
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-3-((E)-2-((1R,3R,4S)-4-chloro-3-methoxycyclohexyl)-1-methylvinyl)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,26,26a-hexadecahydro-5,19-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,17,20,21(4H,23H)-tetrone
137071-32-0
33-Epi-chloro-33-desoxyascomycin
33-epi-Chloro-33-desoxyascomycin
ASM 981
ASM-981
ASM-998
CHEMBL1200686
CID6447131
CID6509979
CID6916008
D05480
DB00337
 
Elidel
Elidel (TN)
I06-1252
LS-181798
MolPort-003-666-749
NCGC00167506-01
Pimecrolimus
Pimecrolimus (JAN/USAN/INN)
Pimecrolimus [USAN:INN:BAN]
Pimecrolimusum
S5004_Selleck
SDZ ASM 981
SDZ-ASM 981
SDZ-ASM-981
UNII-7KYV510875
26
AtropinePhase 4, Phase 2, Phase 3, Phase 1, Phase 01205908-99-6, 51-55-8174174
Synonyms:
(+,-)-Tropyl tropate
(+-)-Atropine
(+-)-Hyoscyamine
(+-)-atropine
(+-)-hyoscyamine
(+/-)-Atropine
(+/-)-Hyoscyamine
(3-Endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol
(3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[3.2.1]octane
(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol
(±)-atropine
(±)-hyoscyamine
1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester)
1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI)
120-29-6
1alphaH,5alphaH-Tropan-3alpha-ol
1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester)
1alphaH,5alphaH-Tropan-3beta-ol
2-Phenylhydracrylic acid 3-alpha-tropanyl ester
51-55-8
8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropionate
A0132_SIGMA
A2468_SIGMA
AC1L5AX3
AC1Q3XL2
ACon1_000046
AI3-60219
AKOS005137976
ATROPINE
Ambap120-29-6
Anaspaz
Atropair
Atropen
Atropen (TN)
Atropin
Atropin [German]
Atropin-flexiolen
Atropina
Atropina [Italian]
Atropine
Atropine (USP)
Atropine Care
Atropine Sulfate
Atropine Sulfate S.O.P.
Atropine [BAN]
Atropinol
Atropinum
Atropt
Atrosulf
BRD-A27290375-001-01-8
Belladenal
Bellergal-S
Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester
C01479
C17H23NO3
CAS-120-29-6
CCRIS 3080
CHEBI:15742
CHEBI:15884
CHEBI:16684
CHEBI:537621
CHEBI:57858
CHEMBL1235490
 
CID174174
CPD001906768
Cytospaz
D00113
DB00572
DB04026
DL-Hyoscyamine
DL-Tropanyl 2-hydroxy-1-phenylpropionate
DL-Tropyl tropate
EINECS 200-104-8
Eyesules
FT-0082634
HMS2089A16
HSDB 2199
Hyoscyamine sulfate
I-Tropine
Isopto Atropine
Isopto-atropine
LS-7203
MEGxp0_001878
MLS000069795
MLS001148094
MLS002695888
Minims
Minims Atropine
MolPort-001-742-593
MolPort-003-986-158
Mydriasine
NCGC00016370-01
NCGC00142514-01
NCGC00142514-03
NP-010662
Neo-Diophen
OR22908
Ocu-Tropine
Protamine & Atropine
SAM002554885
SMR000058248
ST057178
ST057655
T0534
TL8000018
Tropanol
Tropic acid, 3-alpha-tropanyl ester
Tropic acid, ester with tropine
Tropine (+/-)-tropate
Tropine tropate
Tropine, tropate (ester)
Troyl tropate
Urised
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
[(1S,5R)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate
[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate
a-Tropine
atropinium cation
atropinium(1+)
b eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]
beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]
bmse000649
d1-hyoscyamine
dl-Hyoscyamine
dl-Tropyltropate
dl-tropyltropate
endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
endo-8-methyl-8-azabicyclo[3.2.1]octan-3-ol
hyoscyamine
nchembio.307-comp21
tropan-3alpha-ol
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate
tropan-3beta-ol
27
RemifentanilPhase 4430132875-61-760815
Synonyms:
1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester
132539-07-2 (mono-hydrochloride)
132875-61-7
3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
AC1L1TZ8
AC1Q5ZGR
BIDD:GT0029
C08021
CHEBI:8802
CHEMBL1005
CID60815
D08473
DB00899
 
DEA No. 9739
GI 87084B
GI 87084X
GI87084B
L001266
LS-115982
MolPort-004-286-006
REMIFENTANIL
Remifentanil (INN)
Remifentanil [INN:BAN]
Remifentanyl
UNII-P10582JYYK
Ultiva
Ultiva (TN)
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
28
RocuroniumPhase 4, Phase 3251119302-91-9, 143558-00-3441290
Synonyms:
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane
143558-00-3
AC1L9AWM
BIDD:GT0360
C07556
CHEBI:8884
CID441290
 
DB00728
Esmeron
HMS2090E03
NCGC00167433-01
Rocuronium
Rocuronium bromide
Zemuron
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
29
BetamethasonePhase 4, Phase 3, Phase 2, Phase 1165378-44-99782
Synonyms:
.beta.-Methasone
.beta.-Methasone alcohol
1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol
16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
24024-03-1
34166_FLUKA
34166_RIEDEL
378-44-9
4-08-00-03501 (Beilstein Handbook Reference)
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
9-Fluoro-16.beta.-methylprednisolone
9-Fluoro-16beta-methylprednisolone
9-Fluoro-16β-methylprednisolone
9-alpha-Fluoro-16-beta-methylprednisolone
9.alpha.-Fluoro-16.beta.-methylprednisolone
9alpha-Fluoro-16 beta-methyl-prednisolone
9alpha-Fluoro-16beta-methylprednisolone
9α-Fluoro-16β-methylprednisolone
AC1L1EYE
AC1L1TT4
AC1Q5HJZ
AKOS001582690
AR-1A7284
AR-1H5595
B1837
B7005_SIAL
B7005_SIGMA
B9675_SIAL
BIDD:PXR0047
BPBio1_000533
BRD-A35108200-001-04-7
BRD-K39188321-001-03-9
BRN 3176546
BSPBio_000483
Bebate
Becort
Bedifos
Betacorlan
Betacortril
Betadexamethasone
Betafluorene
Betamamallet
Betametasona
Betametasona [INN-Spanish]
Betametasone
Betametasone [DCIT]
Betamethasone
Betamethasone (JP15/USP/INN)
Betamethasone Base
Betamethasone Valearate
Betamethasone [USAN:BAN:INN:JAN]
Betamethasone [USAN:INN:BAN:JAN]
Betamethasone alcohol
Betamethasone cream
Betamethasonum
Betamethasonum [INN-Latin]
Betamethasonvalerat Mikron
Betamethazone
Betapredol
Betasolon
Betnelan
 
Betsolan
C22H29FO5
CHEBI:3077
CHEMBL632
CID3003
CID9782
CPD000339803
Celestene
Celeston
Celestona
Celestone
Celestone Syrup and Tablets
Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone
Cellestoderm
Cidoten
D00244
D1961
DB00443
Desacort-Beta
EINECS 206-825-4
Flubenisolone
HMS1569I05
HSDB 3015
Hormezon
I06-0121
KST-1A3042
LS-118466
LT00441022
Luxiq
Luxiqo
MLS-0310139.0001
MLS000686794
MLS000859943
MLS001066413
MLS001332616
MLS002153244
Methazon
MolPort-003-845-025
MolPort-007-981-051
NCGC00164401-01
NCGC00164401-02
NSC 39470
NSC-39470
NSC39470
Prestwick0_000362
Prestwick1_000362
Prestwick2_000362
Prestwick3_000362
Prestwick_703
Rinderon
Rinderon (TN)
Rinderon A
S1500_Selleck
SAM002589959
SCH 4831
SCH-4831
SMP1_000043
SMR000058601
SMR000339803
SPBio_002404
UNII-9842X06Q6M
Valisone
Visubeta
ZINC03876136
beta-Methasone
beta-Methasone alcohol
betamethasone
30
MemantinePhase 417619982-08-24054
Synonyms:
1,3-Dimethyl-5-adamantanamine
1-Amino-3,5-dimethyladamantane
19982-08-2
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyladamantan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
BBL000737
BPBio1_001117
BPBio1_001270
BSPBio_001015
Biomol-NT_000209
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DMAA
DivK1c_000068
EU-0053634
Ebixa
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
 
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
LS-157051
Lopac0_000861
Memantin
Memantina
Memantina [INN-Spanish]
Memantine
Memantine (INN)
Memantine HCL
Memantine Hydrochloride
Memantine [INN:BAN]
Memantine [INN]
Memantinum
Memantinum [INN-Latin]
MolPort-002-041-858
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Namenda
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
ST057652
STK520682
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
Spectrum_000607
UNII-W8O17SJF3T
ZERO/006024
memantine
31
TreprostinilPhase 4, Phase 3, Phase 28281846-19-754786, 6918140
Synonyms:
((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate
(1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid
({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid
15 AU81
15AU81
2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
289480-64-4 (Sodium salt)
81846-19-7
AC1L1HPX
AC1OCF2J
CHEBI:50861
CID11246284
CID54786
CID6918140
CID9800580
D06213
DB00374
L001079
 
LRX 15
LS-177654
LS-187014
LS-187645
Remodulin (TN)
Treprostinil
Treprostinil (USAN/INN)
Treprostinil [USAN:INN]
Treprostinil sodium
Treprostinilo
Treprostinilum
U 62840
U-62,840
UNII-RUM6K67ESG
UT-15
Uniprost
Viveta
[[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid
treprostinilo
treprostinilum
32
NaproxenPhase 4, Phase 2, Phase 3, Phase 124822204-53-11302, 156391
Synonyms:
(+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(+)-(S)-Naproxen
(+)-2-(6-Methoxy-2-naphthyl)propionic acid
(+)-2-(Methoxy-2-naphthyl)-propionic acid
(+)-2-(Methoxy-2-naphthyl)-propionsaeure
(+)-2-(Methoxy-2-naphthyl)-propionsaeure [German]
(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(+)-Naproxen
(+)NAPROXEN
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
(S)-()-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-()-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-(+)-Naproxen
(S)-2-(6-Methoxy-2-naphthyl)propanoic acid
(S)-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid
(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-Naproxen
2-(6-Methoxy-2-naphthyl)propionic acid
2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)- (8CI)
22204-53-1
284785_ALDRICH
46482_FLUKA
46482_RIEDEL
65126_FLUKA
AC-1363
AC1L4G3X
AC1Q4ET9
AC1Q4F4H
AC1Q4F4I
ARONIS24306
Acusprain
Aleve
Anaprox
Anax
Anexopen
Apo-Napro-NA
Apo-Naproxen
Apronax
Artagen
Arthrisil
Artrixen
Artroxen
Atiflan
Axer
BIDD:GT0062
BRD-K59197931-001-02-9
BRD-K59197931-236-09-6
BSPBio_002067
Bipronyl
Bonyl
CAS-22204-53-1
CCRIS 5265
CG 3117
CHEBI:7476
CHEMBL154
CID156391
Calosen
Clinosyn
Congex
D-Naproxen
DB08298
DL Naproxen
DL-Naproxen
Danaprox
Daprox
Diocodal
DivK1c_000242
Duk
Dysmenalgit
Dysmenalgit N
EINECS 244-838-7
Ec-Naprosyn
Equiproxen
Equiproxen (Veterinary)
FT-0082415
Flanax Forte
Flexen
Flexipen
Floginax
Fuxen
Genoxen
HMS1920P13
HMS2089N21
HMS2091H12
HMS500M04
HSDB 3369
Headlon
IDI1_000242
InChI=1/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
KBio1_000242
KBio2_001457
KBio2_004025
KBio2_006593
KBio3_001567
KBioGR_000597
KBioSS_001457
LS-124738
Laraflex
 
Lefaine
Leniartil
Lopac0_000792
M1021
Methoxypropiocin
MolPort-000-145-960
N8280_SIAL
NAPROXEN
NCGC00016759-01
NCGC00021127-01
NCGC00161591-01
NINDS_000242
NPS
Nafasol
Naixan
Nalyxan
Napflam
Napmel
Naposin
Napratec
Naprelan
Napren
Napren E
Naprius
Naprolag
Naprontag
Naprosin
Naprosyn LLE
Naprosyn LLE Forte
Naprosyne
Naproxen
Naproxen Sodium
Naproxen [USAN:BAN:INN:JAN]
Naproxene
Naproxene [INN-French]
Naproxeno
Naproxeno [INN-Spanish]
Naproxenum
Naproxenum [INN-Latin]
Naproxi 250
Naproxi 500
Naproxène
Napxen
Narma
Narocin
Naxen
Naxen F
Naxopren
Naxyn
Naxyn 250
Naxyn 500
Noflam
Novonaprox
Nycopren
Opipramol
Patxen
Prafena
Prestwick0_000791
Prestwick1_000791
Prestwick2_000791
Prestwick_349
Prexan
Priaxen
Pronaxen
Proxen LE
Proxen LLE
RS 3540
RS-3540
Rahsen
Reuxen
Rheumaflex
Roxen
SPBio_000966
SPBio_002861
SPECTRUM1500425
SR-01000075977-3
STOCK1N-50633
Saritilron
Sinartrin
Sinton
Soproxen
Spectrum2_001043
Spectrum3_000514
Spectrum4_000069
Spectrum5_001327
Spectrum_000977
Sutolin
Sutony
TL8003659
Tohexen
Traumox
U-Ritis
UNII-57Y76R9ATQ
UPCMLD-DP001
UPCMLD-DP001:001
Velsay
Veradol
Vinsen
Xenar
d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure
d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure [German]
d-2-(6-Methoxy-2-naphthyl)propionic acid
d-Naproxen
33
BradykininPhase 4, Phase 34958-82-2439201
Synonyms:
Callidin I
Kallidin 9
 
Kallidin I
L-Arginyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phenylalanyl-L-Arginine
L-Bradykinin
34
IcatibantPhase 4, Phase 316138614-30-9, 130308-48-471364
Synonyms:
(2S)-2-[[(3aS,7aS)-1-[2-[(2S)-2-[[(2S)-2-[[2-[[(4R)-1-[1-[2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
(2s)-2-({[(3as,7as)-1-({2-[(2s)-2-{[(2s)-2-({[({(4r)-1-[(1-{2-({(2r)-2-amino-5-[(diaminomethylidene)amino]pentanoyl}amino)-5-[(diaminomethylidene)amino]pentanoyl}pyrrolidin-2-yl)carbonyl]-4-hydroxypyrrolidin-2-yl}carbonyl)amino]acetyl}amino)-3-(thiophen-2-yl)propanoyl]amino}-3-hydroxypropanoyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}carbonyl)octahydro-1h-indol-2-yl]carbonyl}amino)-5-[(diaminomethylidene)amino]pentanoic acid(non-preferred name)
130308-48-4
138614-30-9 (acetate)
13996-86-6
153322-84-0
AC1L2G0Q
AC1Q5QRX
AR-1A3141
C59H89N19O13S
CHEBI:163731
CHEMBL411169
 
CID71364
D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK
DB06196
Firazyr
HOE 140
HOE140
Hoe-140
Icatibant
Icatibant [INN]
JE049
KST-1A1301
LS-172762
WIN 65365
WIN-65365
35
IloprostPhase 4, Phase 1, Phase 2, Phase 07778919-13-86443959
Synonyms:
(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid
(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
73873-87-7
78919-13-8
AC1NSK5T
AC1O5JIJ
AC1O5JP3
AC1Q1J28
ACT-213105
C22H32O4
CHEMBL138694
CHEMBL236025
CHEMBL494
CID10937300
CID11639089
CID5311181
CID6435293
CID6435378
CID9885245
 
CID9975807
Ciloprost
D02721
E-1030
Endoprost
HMS2090A19
ILOPROST
Ilomedin
Ilomedine
Iloprost
Iloprost (INN)
Iloprost [BAN:INN]
Iloprostum
Iloprostum [Latin]
L000996
LS-101845
NCGC00181784-01
PDSP2_001536
SH-401
UNII-JED5K35YGL
Ventavis
Ventavis (TN)
ZK 36374
ZK-36374
ZK-363775
[3H]-Iloprost
36Betamethasone ValeratePhase 4, Phase 3, Phase 2, Phase 11652152-44-5
37CALCIPOTRIENEPhase 4, Phase 3, Phase 2, Phase 196
38
TerfenadinePhase 4, Phase 3, Phase 14850679-08-85405
Synonyms:
(RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol
.alpha.-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenyl-methyl)-1-piperidine butanol
1-(4-tert-Butylphenyl)-4-(4-(alpha-hydroxybenzhydryl)piperidino)-butan-1-ol
1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol
1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol
1-(p-tert-Butylphenyl)-4-(4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl)butanol
1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol
50679-08-8
AB00052367
AC-15791
AC1L1KA8
AC1Q1LZA
Aldaban
Aliud Brand of Terfenadine
Allerplus
BIM-0051180.0001
BPBio1_000238
BRD-A06352418-001-03-6
BRN 5857899
BSPBio_000216
Balkis Saft Spezial
Bial Brand of Terfenadine
C07463
C32H41NO2
CHEBI:119569
CHEMBL17157
CID5405
Cantabria Brand of Terfenadine
Cyater
D00521
D016593
DB00342
DivK1c_001011
Dolorgiet Brand of Terfenadine
EINECS 256-710-8
EU-0101213
HMS1568K18
HMS2089I14
HMS2093I11
HMS503K03
HSDB 6508
Heumann Brand of Terfenadine
Hisfedin
Hoechst Brand of Terfenadine
IDI1_001011
KBio1_001011
L000888
LS-114369
Lopac0_001213
MDL 9918
MDL-9918
MLS000028499
MLS001148415
Merck dura Brand of Terfenadine
MolPort-002-904-065
Mundipharma Brand of Terfenadine
NCGC00016064-04
NCGC00016064-08
NCGC00089746-02
 
NCGC00089746-03
NCGC00089746-04
NCI60_022784
NINDS_001011
NSC665802
Oprea1_343139
Prestwick0_000138
Prestwick1_000138
Prestwick2_000138
Prestwick3_000138
Prestwick_460
RMI 9918
RMI-9918
RMI9918
Rapidal
SMR000058260
SPBio_002155
ST50307835
Seldane
Seldane (TN)
Sigma Tau Brand of Terfenadine
Sigma-Tau Brand of Terfenadine
Stadapharm Brand of Terfenadine
T 9652
T9652_SIGMA
Teldane
Teldanex
Terdin
Terfedura
Terfemundin
Terfen
Terfenadin
Terfenadin AL
Terfenadin Heumann
Terfenadin Stada
Terfenadin-ratiopharm
Terfenadina
Terfenadina [INN-Spanish]
Terfenadine
Terfenadine (JAN/USAN/INN)
Terfenadine [USAN:BAN:INN:JAN]
Terfenadinum
Terfenadinum [INN-Latin]
Terfenidine
Terfex
Terfénadine
Ternadin
Triludan
UNII-7BA5G9Y06Q
Wolff Brand of Terfenadine
alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol
alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
alpha-(4-[1,1-Dimethylethyl]phenyl)-4-[hydroxydiphenylmethyl]-1-piperidinebutanol
alpha-(p-tert-Butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol
ct Arzneimittel Brand of Terfenadine
ct-Arzneimittel Brand of Terfenadine
ratiopharm Brand of Terfenadine
terfenadin von ct
terfenadine
39
DexmedetomidinePhase 4, Phase 351576631-46-4, 113775-47-668602, 5311068, 56032
Synonyms:
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
113775-47-6
4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
DEXMEDETOMIDINE
 
Dexdor (T)
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
Dexmedetomidine (USAN/INN)
Dexmedetomidinum
Dexmédétomidine
MPV 1440
MPV-1440
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
NCGC00025347-01
PRECEDEX
Precedex (TN)
Tocris-2023
ZINC04632106
40
lactitolPhase 4, Phase 3, Phase 2325585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
41
MiconazolePhase 4, Phase 2, Phase 3, Phase 1357322916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
42
FexofenadinePhase 4, Phase 3, Phase 15983799-24-03348
Synonyms:
159389-12-5
2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid
2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid
76815-58-2
83799-24-0
AC1L1FQB
Allegra
Allegra-D 12 Hour
Allegra-D 24 Hour
BRD-A73368467-003-02-8
BSPBio_003521
C06999
C32H39NO4
CHEBI:5050
CHEMBL914
CID3348
Carboxyterfenadine
D07958
DB00950
EU-0100488
F 9427
Fexofenadine
Fexofenadine (INN)
Fexofenadine [INN:BAN]
Fexofenadine hydrochloride
Fexofendine
HSDB 7486
KBio2_002449
 
KBio2_005017
KBio2_007585
KBio3_002742
KBioGR_000807
KBioSS_002456
L000869
LS-28827
Lopac0_000488
MDL 16455
MolPort-002-508-207
NCGC00015453-03
NCGC00015453-06
NCGC00092389-02
NCGC00092389-03
SPBio_001197
STK624102
STOCK6S-26154
Spectrum2_001179
Spectrum3_001921
Spectrum4_000204
Spectrum5_001474
Spectrum_001914
Telfast
Telfast (TN)
Terfenadine acid metabolite
Terfenadine carboxylate
Terfenadine-COOH
Terfenidine carboxylate, MDL 16455
UNII-E6582LOH6V
fexofenadine
43
RopivacainePhase 4, Phase 3, Phase 2, Phase 170984057-95-471273, 175805
Synonyms:
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
(S)-(−)-1-propyl-2',6'-pipecoloxylidide
(S)-ropivacaine
84057-95-4
98717-15-8
AC1L41QM
AC1L41QN
BIDD:GT0203
C07532
C17H26N2O.HCl
CHEBI:8890
CHEMBL1077896
CID175804
CID175805
CPD000469137
D08490
I14-176
L-N-n-propylpipecolic acid-2,6-xylidide
LS-113954
 
MLS001401363
MolPort-003-983-292
NCGC00164597-01
Naropin
Naropin (TN)
ROPIVACAINE HCl
Ropivacaina
Ropivacaina [INN-Spanish]
Ropivacaina [Spanish]
Ropivacaine
Ropivacaine [INN]
Ropivacaine hydrochloride
Ropivacaine monohydrochloride
Ropivacainum
Ropivacainum [INN-Latin]
S-Ropivacaine
SAM001246524
SMR000469137
ST51051452
ropivacaine monohydrochloride,
ropivacaine monohydrochloride, (S)-isomer
44
ClobetasolPhase 4, Phase 17325122-46-732798, 5311051
Synonyms:
(11beta,16beta)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
(9R,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
25122-41-2
AC-1775
AC1L1OG6
AC1NDRJ9
AC1NSJWK
BB_NC-1906
C22H28ClFO4
CHEBI:205919
CHEMBL1201362
CID10341542
CID32797
 
CID4630419
CID5311051
CID9844480
Clobecort Amex
Clobecort Amex (TN)
Clobetasol (INN)
Clobetasol [INN:BAN]
Clobetasolum
Clobetasolum [INN-Latin]
Clofenazon
D07715
EINECS 246-633-8
LS-174086
MolPort-005-909-335
NCGC00164580-01
STK801976
UNII-ADN79D536H
ZINC26892643
clobetasol
45
LidocainePhase 4, Phase 3, Phase 2, Phase 1, Phase 01168137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
46
BupivacainePhase 4, Phase 2, Phase 3, Phase 110562180-92-9, 38396-39-32474
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
(±)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
15233-43-9
2180-92-9
38396-39-3
AB00053674
AC-2096
AC1L1DRE
AC1Q5LX4
AH 250
AKOS001637202
AR-1A0242
Anekain
BPBio1_000298
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bio-0886
Bloqueina
Bucaine
Bucaine (TN)
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaine (INN)
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL KIT
Bupivacaine Monohydrochloride, Monohydrate
Bupivacaine [INN:BAN]
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
C07529
C18H28N2O
CBupivacaine
CHEBI:3215
CHEMBL1098
CID2474
Carbostesin
D07552
DB00297
DL-Bupivacaine
DUR-843
 
DepoBupivacaine
DivK1c_000758
EINECS 218-553-3
EINECS 253-911-2
HMS2090F12
IDI1_000758
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
MLS001361336
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
SMR000058218
SPBio_001558
SPBio_002489
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Spectrum_001524
Transdur-Bupivacaine
UNII-Y8335394RO
Win 11318
Win 11318 HCl
bupivacaine
cBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
racemic bupivacaine
47
LevobupivacainePhase 4, Phase 316027262-47-192253
Synonyms:
(-)-Bupivacaine
(-)-bupivacaine
(2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(S)-1-Butyl-2',6'-pipecoloxylidide
(S)-Bupivacaine
(S)-bupivacaine
27262-47-1
27262-48-2
AC1L3NQM
BIDD:GT0471
C07887
C18H28N2O
CAS-18010-40-7
CHEBI:6149
CID92253
D08116
 
DB01002
L(-)-Bupivacaine
L-(-)-1-Butyl-2',6'-pipecoloxylidide
L-(-)-Bupivacaine
L-(-)-bupivacaine
LS-109843
LS-187025
LS-187789
Levobupivacaine
Levobupivacaine (INN)
Levobupivacaine [INN:BAN]
Levobupivacaine hydrochloride
MolPort-004-959-713
NCGC00016733-01
NCGC00159482-02
Novabupi
Novabupi (TN)
48
CalcitriolPhase 4, Phase 3, Phase 2, Phase 119432222-06-3134070, 5280453
Synonyms:
(1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
(1S,3R,5Z,7e)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1alpha,3beta,5Z,7e)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol
(5Z,7e)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
1 alpha,25-Dihydroxyvitamin D3
1,25 (OH)2 D3
1,25 Dihydroxycholecalciferol
1,25(OH)2-20epi-D3
1,25(OH)2D3 & CD4
1,25(OH2)D3
1,25-(OH)2-D3
1,25-(OH)2D3
1,25-DHCC
1,25-DIHYDROXYCHOLECALCIFEROL
1,25-Dihydroxycholecalciferol
1,25-Dihydroxycholecaliferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1,25-dihydroxy vitamin D3
1,25-dihydroxy-20-epi-Vitamin D3
1,25-dihydroxycholecalciferol
1,25D3
1-alpha,-1,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxycholecalciferol
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1-alpha-25-dihydroxyvitamin D3
1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3
17936_FLUKA
17936_SIGMA
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1alpha,25(OH)2-D3
1alpha,25(OH)2D3
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D
1alpha,25-Dihydroxyvitamin D3
1db1
1α,25(OH)2D3
1α,25-dihydroxycholecalciferol
1α,25-dihydroxyvitamin D3
20-epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
32222-06-3
5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol
9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4
9,10-seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha, 3beta, 25-triol
AC-1859
AC1NQX1S
 
Ambap32222-06-3
Asentar
BCBcMAP01_000160
BML2-E03
BSPBio_001287
C01673
CCRIS 5522
CD-2027
CHEBI:17823
CHEMBL846
CID5280453
CPD000466393
Calcijex
Calcijex, Silkis, Rocaltrol, Topitriol, Cholecalciferol,Calcitriol
Calcitriol
Calcitriol (JAN/USAN/INN)
Calcitriol [USAN:INN:BAN:JAN]
Calcitriolum
Calcitriolum [INN-Latin]
D00129
D1530_SIGMA
DN 101
DN-101
Decostriol
Dihydroxyvitamin D3
EINECS 250-963-8
HMS1361A09
HMS1791A09
HMS1989A09
HMS2051F06
HMS2089N03
HSDB 3482
IDI1_033757
LMST03020258
LS-53093
MC-1288
MC1288
MLS000759536
MLS001424122
MolPort-002-045-698
NCGC00161327-01
NCGC00161327-04
Ro 21-5535
Ro 215535
Ro-21-5535
Rocaltrol
Rocaltrol (TN)
S1466_Selleck
SAM001246772
SMR000466393
Silkis
Soltriol
Spectrum5_002061
Topitriol
Toptriol
U 49562
Vectical
ZINC03924790
calcitriol
vit D
49
DiclofenacPhase 4, Phase 330315307-86-53033
Synonyms:
(2,6-Dichlorophenyl)amino]benzeneacetic acid
15307-81-0 (mono-potassium salt)
15307-86-5
2-((2,6-Dichlorophenyl)amino)benzeneacetic acid
2-((2,6-dichlorophenyl)amino)benzeneacetic acid
2-(2,6-Dichloroanilino)phenylacetic Acid
2-(2,6-Dichlorophenylamino)phenylacetic acid
2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid
2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID
2-[2-(2,6-Dichlorophenylamino)phenyl]acetic acid
2-[2-(2,6-dichloroanilino)phenyl]acetic acid
2b17
AC1L1F0T
AKOS001579542
Acetic acid, [o-(2,6-dichloroanilino)phenyl]- (8CI)
Allvoran
Apo-Diclo
Assaren
BIDD:GT0380
BPBio1_000516
BRD-K08252256-236-05-6
BRN 2146636
BSPBio_000468
BSPBio_002169
Benfofen
Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)- (9CI)
C01690
CHEBI:47381
CHEMBL139
CID3033
Cataflam
D07816
D30801
D3748
DB00586
DIF
Delphimix
Dichlofenac
Dichlofenal
Dichronic
Diclac
Diclo-Phlogont
Diclo-Puren
Diclobenin
Diclofenac (INN)
Diclofenac Acid
Diclofenac Potassium
Diclofenac Sodium
Diclofenac [INN:BAN]
Diclofenac acid
Diclofenaco
Diclofenaco [INN-Spanish]
Diclofenacum
Diclofenacum [INN-Latin]
Diclofenamic acid
Diclomelan
Diclonate P
Diclophenac
Diclord
Dicloreum
Dicloreuma
Dicrofenac
DivK1c_000272
DivK1c_000402
Dolobasan
Duravolten
Dyloject
EINECS 239-348-5
Ecofenac
Effekton
GP-45,840
HMS2090C10
HMS501E04
HSDB 7234
I14-7739
 
IDI1_000272
IDI1_000402
ISV-205
KBio1_000272
KBio1_000402
KBio2_001410
KBio2_002306
KBio2_003978
KBio2_004874
KBio2_006546
KBio2_007442
KBio3_001389
KBio3_002786
KBioGR_001051
KBioGR_002306
KBioSS_001410
KBioSS_002308
Kriplex
LS-11575
Lopac0_000441
MolPort-000-003-072
N-(2,6-Dichlorop
NCGC00021125-01
NINDS_000272
NINDS_000402
Neriodin
Novapirina
Novo-Difenac
Novo-Difenac SR
Nu-Diclo
Oprea1_011155
Orthofen
Pennsaid
Prestwick0_000594
Prestwick1_000594
Prestwick2_000594
Prestwick3_000594
Primofenac
ProSorb-D
Prophenatin
Rhumalgan
SBB068617
SPBio_001081
SPBio_002687
SR-38
STK984493
Solaraze
Solaraze (TN)
Solaraze T
Spectrum2_000991
Spectrum3_000385
Spectrum4_000506
Spectrum5_000867
Spectrum_000930
Transfenac
Tsudohmin
UNII-144O8QL0L1
UNM000001216103
Valetan
Voldal
Voltaflan
Voltaren
Voltaren Ophtha
Voltaren Ophthalmic
Voltaren Rapide
Voltaren SR
Voltaren ophthalmic
Voltaren-XR
Voltarol
Xenid
[2-(2,6-dichloroanilino)phenyl]acetic acid
[o-(2,6-Dichloroanilino)phenyl]acetic acid
cMAP_000014
dichlofenac
diclofenac
henyl)-o-aminophenylacetic acid
{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid
50
LoratadinePhase 4, Phase 3, Phase 19079794-75-53957
Synonyms:
1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester
1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester
1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester
1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester
4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester
4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
79794-75-5
AC-2086
AC1L1H3E
Aerotina
Alarin
Alavert
Alavert, Claritin, Loratadine
Alerpriv
Allertidin
Amantadine
Anhissen
BB_SC-2109
BIDD:GT0198
BRD-K82795137-001-02-3
BRD-K82795137-001-10-6
BSPBio_002300
Bedix Loratadina
Biloina
Bonalerg
C22H23ClN2O2
CHEMBL998
CID3957
CPD000058255
Children's Claritin
Civeran
Claratyne
Claratyne Cold
Claratyne Decongestant
Clarinase
Clarinase Reperabs
Claritin
Claritin (TN)
Claritin D
Claritin Hives Relief
Claritin Hives Relief Reditab
Claritin Reditabs
Claritin reditab
Claritine
Clarityn
Clarityne
Clarityne Dy Repetabs
Clarityne-D
Clarium
Cronopen
D00364
D017336
DB00455
DivK1c_000792
EU-0100680
Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate
Flonidan
Fristamin
HMS2051G11
HMS2090O18
HMS2093I15
HMS502H14
HSDB 3578
Histaloran
I14-0747
IDI1_000792
KBio1_000792
KBio2_001976
KBio2_004544
KBio2_007112
KBio3_001520
KBioGR_000693
KBioSS_001976
Klaritin
L 9664
L000667
L0223
L9664_SIGMA
LS-114660
 
Lergy
Lertamine
Lesidas
Lisino
Lopac-L-9664
Lopac0_000680
Loracert
Loradex
Loradif
Loranox
Lorantis
Lorastine
Loratadina
Loratadina [Spanish]
Loratadine
Loratadine (JAN/USAN/INN)
Loratadine Redidose
Loratadine Wyeth Brand
Loratadine [USAN:BAN:INN]
Loratadinum
Loratadinum [Latin]
Loratidine
Loratyne
Loraver
Lorfast
Loritine
Lowadina
MLS000069647
MLS000758260
MLS001148466
MolPort-002-507-846
NCGC00015619-01
NCGC00015619-02
NCGC00015619-06
NCGC00015619-10
NCGC00023125-02
NCGC00023125-04
NCGC00023125-05
NCGC00023125-06
NCGC00023125-07
NCI60_041473
NINDS_000792
NSC721075
Nularef
Oprea1_027965
Optimin
Polaratyne
Pylor
Restamine
Rhinase
Rinomex
Roletra
S1358_Selleck
SAM001246987
SMR000058255
SPBio_001548
SPECTRUM1503712
STK574925
Sanelor
Sch 29851
Sch-29851
Sch29851
Sensibit
Sinhistan Dy
Sohotin
Spectrum2_001584
Spectrum3_000740
Spectrum4_000177
Spectrum5_001650
Spectrum_001496
TL8005389
Tadine
Talorat Dy
Tocris-1944
UNII-7AJO3BO7QN
Velodan
Versal
Wyeth Brand of Loratadine
ZINC00537931
Zeos
ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate
loratadine

Interventional clinical trials:

(show top 50)    (show all 5018)
idNameStatusNCT IDPhase
1Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic AsthmaCompletedNCT00264849Phase 4
2Asthma Comparative Effectiveness StudyCompletedNCT01623544Phase 4
3Inner-City Anti-IgE Therapy for AsthmaCompletedNCT00377572Phase 4
4Budesonide Inhalation Suspension for Acute Asthma in ChildrenCompletedNCT00393367Phase 4
5A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma ControlCompletedNCT00351143Phase 4
6Small Airways Involvement in Smoker Asthmatic Patients: a Pilot StudyCompletedNCT01620099Phase 4
7Real Life Effectiveness in Patients With Not Optimally Controlled AsthmaCompletedNCT01647646Phase 4
8Efficacy of a Minimal Intervention Educational Program in the Asthma Control and Exacerbations PreventionCompletedNCT01282359Phase 4
9Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)CompletedNCT00404547Phase 4
10Preventative Omalizumab or Step-up Therapy for Severe Fall ExacerbationsCompletedNCT01430403Phase 4
11Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic AsthmaCompletedNCT00567476Phase 4
12MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and AdultsCompletedNCT00242411Phase 4
13Asthma in the Elderly: The Effect of MontelukastCompletedNCT02635334Phase 4
14RCT of a Written Action Plan vs. Usual Care in Children With Acute AsthmaCompletedNCT00381355Phase 4
15Study of Safety of Foradil in Patients With Persistent AsthmaCompletedNCT01845025Phase 4
16Does Tailored Education in Asthma Care Help Improve Patient Satisfaction, Adherence, and Quality of Life (TEACH) TrialCompletedNCT00687310Phase 4
17SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.CompletedNCT01475721Phase 4
18Oral Prednisolone Dosing in Children Hospitalized With AsthmaCompletedNCT00257933Phase 4
19Study Of Asthma In Patients Of African DescentCompletedNCT00102765Phase 4
20Trial of Asthma Patient Education (TAPE)CompletedNCT00148408Phase 4
21Inhaled Steroid Treatment as Regular Therapy in Early AsthmaCompletedNCT00641914Phase 4
22Management of Asthma in School-age Children on TherapyCompletedNCT01526161Phase 4
23Study of Asthma and Nasal SteroidsCompletedNCT01118312Phase 4
24Prednisolone Pharmacokinetics in Severe AsthmaCompletedNCT00662298Phase 4
25Improvement of FeNO and FEF25-75 After Inhaled Corticosteroid Treatment of AsthmaCompletedNCT01340118Phase 4
26A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary DiseaseCompletedNCT00862641Phase 4
27AZISAST Study: AZIthromycin in Severe ASThma StudyCompletedNCT00760838Phase 4
28Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic AsthmaCompletedNCT00870584Phase 4
29Lansoprazole to Treat Children With AsthmaCompletedNCT00442013Phase 4
30Singulair(R) In Asthma And Allergic Rhinitis (0476-383)CompletedNCT00545844Phase 4
31Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With AsthmaCompletedNCT01725360Phase 4
32Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic RhinitisCompletedNCT01550471Phase 4
33Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized PatientsCompletedNCT00627731Phase 4
34Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive DisorderCompletedNCT00621946Phase 4
35Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 Mcg/Dose and Salmeterol 50 Mcg/Dose - ADERE PROJECTCompletedNCT01476059Phase 4
36Viapaed Study In Children And Adolescents With AsthmaCompletedNCT00315744Phase 4
376-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldCompletedNCT01462344Phase 4
38The Effects of Montelukast on Smokers With AsthmaCompletedNCT00712335Phase 4
39Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With AsthmaCompletedNCT00238927Phase 4
40Montelukast in Modulating Exacerbations of Asthma in ChildrenCompletedNCT00196547Phase 4
41Patient Research In Self-Management of Asthma (PRISMA)CompletedNCT00411346Phase 4
42Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With AsthmaCompletedNCT02062463Phase 4
43A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With AsthmaCompletedNCT00452699Phase 4
44A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With AsthmaCompletedNCT00452348Phase 4
45Asthma Control in Elderly Patients With MontelukastCompletedNCT01147510Phase 4
46Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)CompletedNCT00832455Phase 4
47A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.CompletedNCT00858286Phase 4
48Risk Factors Associated to Difficult-to-control AsthmaCompletedNCT01089322Phase 4
49Small Particle Steroids in Refractory AsthmaCompletedNCT01171365Phase 4
50A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With AsthmaCompletedNCT02233803Phase 4

Search NIH Clinical Center for Asthma

Inferred drug relations via UMLS66/NDF-RT44:

Show with subtypes

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Asthma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Asthma:
Bone marrow-derived mesenchymal stem cells for severe refractory asthma
Embryonic/Adult Cultured Cells Related to Asthma:
Mouse bone marrow-derived mesenchymal stem cells (family), PMIDs: 21653527, 20801416


Cochrane evidence based reviews: asthma

Genetic Tests for Asthma

About this section

Genetic tests related to Asthma:

id Genetic test Affiliating Genes
1 Asthma, Susceptibility to25
2 Asthma25

Anatomical Context for Asthma

About this section

MalaCards organs/tissues related to Asthma:

34
Lung, Testes, T cells, Heart, Neutrophil, Smooth muscle, Endothelial

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Asthma:
id TissueAnatomical CompartmentCell Relevance
1 LungTracheaAirway Smooth Muscle Cells Potential therapeutic candidate, affected by disease

Animal Models for Asthma or affiliated genes

About this section

MGI Mouse Phenotypes related to Asthma:

39
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538710.7ADRB2, ALOX5, CCL11, CYSLTR1, HLA-G, IL13
2MP:000538810.7CCL11, CYSLTR1, IL13, IL4R, IL5, NPSR1

Publications for Asthma

About this section

Articles related to Asthma:

(show top 50)    (show all 6289)
idTitleAuthorsYear
1
Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model. (26304061)
2015
2
Prolonged Anti-Orthostatic Hind Limb Unloading and Murine Allergic Asthma. (26388087)
2015
3
Expression and targeting of lymphocyte function-associated antigen 1 (LFA-1) on white blood cells for treatment of allergic asthma. (25341726)
2014
4
Is there a role for macrolides in severe asthma? (24247040)
2014
5
Gene-Gene Interaction Between CCR3 and Eotaxin Genes: The Relationship With Blood Eosinophilia in Asthma. (24404394)
2014
6
Cases of occupational dermatitis and asthma in beauticians that were reported to The Health and Occupation Research (THOR) network from 1996 to 2011. (24934913)
2014
7
Intralobar pulmonary sequestration in an adult female patient mimicking asthma: A case report. (25159547)
2014
8
Effects of taraxasterol on ovalbumin-induced allergic asthma in mice. (23727181)
2013
9
The effect of Qi'ao Decoction on ovalbumin induced and lipopolysaccharide enhanced severe asthma mice and its mechanism. (24345505)
2013
10
Phenotypes determined by cluster analysis in severe orA difficult-to-treat asthma. (24315502)
2013
11
X-linked inhibitor of apoptosis single nucleotide polymorphisms and copy number variation are not risk factors for asthma. (23418891)
2013
12
Siglec-8 and Siglec-F, the new therapeutic targets in asthma. (22324980)
2012
13
Phenotypic characterization of ex vivo CD4+CD25highCD127low immune regulatory T cells in allergic asthma: pathogenesis relevance of their FoxP3, GITR, CTLA-4 and FAS expressions. (23241113)
2012
14
Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene. (22792082)
2012
15
Serum levels of lipoxin A(4) do not predict the development of subsequent asthma among young children with acute bronchiolitis. (21671842)
2011
16
Thiol redox disturbances in children with severe asthma areA associated with posttranslational modification of the transcription factor nuclear factor (erythroid-derived 2)-like 2. (21514635)
2011
17
Naringenin chalcone suppresses allergic asthma by inhibiting the type-2 function of CD4 T cells. (20035147)
2010
18
Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. (20599369)
2010
19
Asthma during pregnancy alters immune cell profile and airway epithelial chemokine release. (19876718)
2010
20
Iron and ferritin concentrations in exhaled breath condensate of children with asthma. (19191143)
2009
21
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. (18686943)
2008
22
Differences in airway cytokine profile in severe asthma compared to moderate asthma. (18071017)
2008
23
Uteroglobin-related protein 1 gene -112G/a polymorphism and atopic asthma in Sicilian children. (18201431)
2007
24
Effect of rosiglitazone on the expression of T-bet/GATA-3 in T lymphocytes in patients with acute asthma]. (17445473)
2007
25
Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. (16724092)
2006
26
IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. (16630936)
2006
27
Interleukin-13 and interleukin-5 in induced sputum of eosinophilic bronchitis: comparison with asthma. (16236836)
2005
28
The relationship between delta-forced vital capacity (percent fall in forced vital capacity at the PC20 dose of methacholine) and the maximal airway response in patients who have mild asthma. (16450571)
2005
29
Potential role of stem cell factor in the asthma control by glucocorticoids. (16107770)
2005
30
Nitric oxide synthase inhibition: therapeutic potential in asthma. (15182209)
2004
31
Plasma eotaxin level and severity of asthma treated with corticosteroid. (15303645)
2004
32
IL-19 induced Th2 cytokines and was up-regulated in asthma patients. (15557163)
2004
33
Discovery and development of respirable antisense therapeutics for asthma. (12162700)
2002
34
Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. (11704612)
2001
35
Management of influenza in patients with asthma or chronic obstructive pulmonary disease. (11770690)
2001
36
Combined ipratropium and beta2--adrenergic receptor agonist in acute asthma. (10682886)
2000
37
Rhinovirus infections: induction and modulation of airways inflammation in asthma. (10421825)
1999
38
Diisocyanate antigen-enhanced production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor-alpha by peripheral mononuclear cells of workers with occupational asthma. (9723671)
1998
39
Effects of some anti-asthma drugs on human eosinophil superoxide anions release and degranulation. (9482706)
1998
40
The level of RANTES and interleukin-8 in serum of children with bronchial asthma after an exercise test]. (9857658)
1998
41
Safety and clinical efficacy of zileuton in patients with chronic asthma. (10181070)
1998
42
Effect of thromboxane A2-receptor antagonist on bradykinin-induced bronchoconstriction in asthma. (8806903)
1996
43
Asthma treatment in pregnancy: a randomized controlled study. (8694041)
1996
44
Allergic bronchopulmonary aspergillosis: an unusual complication of bronchial asthma. (8920604)
1995
45
Allergen-induced CD23 on CD4+ T lymphocytes and CD21 on B lymphocytes in patients with allergic asthma: evidence and regulation. (7910139)
1994
46
Moderating the inflammation of asthma: inhibiting the production or action of products of the 5-lipoxygenase pathway. (8129222)
1994
47
Effect of salbutamol on left ventricular function and selected biochemical parameters in patients with bronchial asthma]. (7854957)
1994
48
Tumor necrosis factor in sputa of patients with bronchial asthma on exacerbation]. (1892447)
1991
49
Aspirin-induced asthma and nasal polyps. (3461681)
1986
50
Pneumothorax and interstitial emphysema in asthma. (14778095)
1950

Variations for Asthma

About this section

Clinvar genetic disease variations for Asthma:

5
id Gene Variation Type Significance SNP ID Assembly Location
1TNFTNF, -308G-Asingle nucleotide variantrisk factor
2IL13IL13, -1112C-Tsingle nucleotide variantrisk factor
3IL13NM_002188.2(IL13): c.431A> G (p.Gln144Arg)single nucleotide variantrisk factorrs20541GRCh37Chr 5, 131995964: 131995964
4SCGB3A2SCGB3A2, -112G/Asingle nucleotide variantrisk factor
5HNMTNM_006895.2(HNMT): c.314C> T (p.Thr105Ile)single nucleotide variantrisk factorrs11558538GRCh37Chr 2, 138759649: 138759649
6SPINK5NM_006846.3(SPINK5): c.1258A> G (p.Lys420Glu)single nucleotide variantrisk factorrs2303067GRCh37Chr 5, 147480955: 147480955
7CCL11CCL11, (GAAGGA)nundetermined variantrisk factor

Copy number variations for Asthma from CNVD:

6 (show all 24)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1142741106371568116327195GainAsthma
2143091107000000111600000DeletionGSTM1Asthma
3185401146397003146438291DeletionNBPF1Asthma
4185411146397003146438291DeletionNBPF10Asthma
5185421146397003146438291DeletionNBPF12Asthma
6185431146397003146438291DeletionNBPF14Asthma
7185441146397003146438291DeletionPPIAL4AAsthma
8259461195089653195163711GainAsthma
954168113824981838282959LossAsthma
1057122116310000076700000DeletionGSTP1Asthma
1173905129843342698580660LossAsthma
1298110161538738016197033GainAsthma
13102400165400048854351802GainAsthma
14113189174200882242137359DeletionARL17Asthma
15113190174200882242137359DeletionARL17AAsthma
16113191174200882242137359DeletionARL17BAsthma
17113192174200882242137359DeletionARL17P1Asthma
18113193174200882242137359DeletionNSFAsthma
19121615184528202447194369GainAsthma
2014714426059173160750244GainAsthma
21161118221729534717792353LossAsthma
22161119221729596319782237LossAsthma
23162464222180000024300000DeletionGSTT1Asthma
241846744179040624179102293GainAsthma

Expression for genes affiliated with Asthma

About this section
Search GEO for disease gene expression data for Asthma.

Pathways for genes affiliated with Asthma

About this section

GO Terms for genes affiliated with Asthma

About this section

Cellular components related to Asthma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular spaceGO:000561510.7ALOX5, CCL11, CHIA, IL13, IL4R, IL5
2extracellular regionGO:000557610.4CCL11, CHIA, IL13, IL5, PLA2G7, RNASE3

Biological processes related to Asthma according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of macrophage activationGO:004303211.1IL13, IL4R
2positive regulation of mast cell degranulationGO:004330611.1IL13, IL4R
3production of molecular mediator involved in inflammatory responseGO:000253210.9CHIA, IL4R
4positive regulation of immunoglobulin productionGO:000263910.9IL13, IL4R
5positive regulation of chemokine secretionGO:009019710.9CHIA, IL4R
6positive regulation of podosome assemblyGO:007180310.8IL5, TNF
7inflammatory responseGO:000695410.6ALOX5, CCL11, IL13, IL5, TNF

Sources for Asthma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet